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Development and validation of a method for the determination of nine 
benzodiazepines and metabolites in dried blood spots (DBS) using UPLC-QTOF-MS 
 
ABSTRACT:  
In forensic toxicology benzodiazepines are common compounds implicated in 
drug impaired driving cases. Detection of these compounds is ideally determined from 
whole blood collected from the individual after impairment has been established and 
qualified personnel are available to draw blood. This study focused on the development 
and validation of a screening method that could also be applied to quantification of a set 
of nine benzodiazepines and metabolites extracted from dried blood spots and analyzed 
using UPLC-QTOF-MS: diazepam (DZP), temazepam (TMZ), oxazepam (OXZ), 
nordiazepam (NOZ), lorazepam (LRZ), clonazepam(CLZ), 7-aminoclonazepam (7CLZ), 
alprazolam (APZ), and α-hydroxyalprazolam (aHAM). Advantages of DBS over whole 
blood sampling are less invasive sampling, potential for increased stability of analytes in 
the card matrix, small sample volumes, simplified extraction and ease of storage and 
transport. All dried blood spots were 20 µL of sheep blood spiked with a 2.86µg/mL 
mixture of the compounds included in this study and left to try overnight at ambient 
temperature. The optimized method immersed a ½” diameter punch of card containing 
the entire blood spot in an extraction solvent of 1:1 (v/v) methanol:acetonitrile and 
sonicated for 30 minutes. The extraction solvent was separated from the spot, 1 mL of 
acetonitrile was added followed by protein filtration. Filtrate was evaporated down to 
dryness and analytes were then reconstituted in 1:1 (v/v) acetonitrile:water before 
analysis. Each step of extraction and sample preparation was optimized for this study. All 
analytes were stable within the card matrix for 14 days under refrigeration at 4°C. All 
analytes were stable up to 12 hours in the autosampler of the instrument. Hematocrit over 
a range of 20 - 70% did not affect interpretation of results. Validation produced 
calibration curves over a range of 7.8 – 500 ng/mL that had R2 values ranging from 
0.998-1.00 with a quadratic line of best fit. Bias was <20% for high blind samples and 
≤25.6% for low blind samples. 
A screening method using UPLC-QTOF-MS to analyze DBS extracts able to 
identify all benzodiazepines of interest was developed and validated. Calibration curves 
representing impairment ranges of the analytes of interest predicted concentrations within 
a reliable range that allowed for quantification of the analytes.  
 
KEYWORDS: forensic science, toxicology, benzodiazepines, dried blood spots, 
UPLC-QTOF-MS 
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CHAPTER 1: INTRODUCTION 
 
1.1 Introduction 
Forensic toxicology is the study of interactions between exogenous compounds, such as 
drugs and poisons, with the biological systems of the body applied within a legal context. This 
is a crucial discipline within forensic science that can produce results with high impact in court. 
There are a few principle case types that are encountered in forensic toxicology: death 
investigations where various post-mortem biological fluids are analyzed, sexual assaults, and 
impaired driving [1]. An increasingly important application of forensic toxicology is to 
impaired driving cases. There has always been a large incidence of cases involving impairment 
by alcohol but over time a steady increase in the number of impairment cases involving drugs 
has been observed [2]. The ideal biological sample collected for these cases is blood. Blood is 
usually the preferred matrix for quantitative analysis, as the drug concentration measured in 
blood is typically best correlated to the concentration of drug at neural receptors. Therefore, the 
impairing effects and the level of impairment are often best correlated with blood drug 
concentration [3-5]. Thus, blood is preferred to urine for cases alleging impairment [4].  
Often the collection of samples is complicated due to an individual’s legal rights, where 
reasonable grounds must be first established before drawing blood.  Drawing blood is an 
intravenous technique; considered highly invasive and requiring trained personnel [5,6]. 
Increases in analytical sensitivity through tandem (MS/MS) and high resolution (e.g. qTOF) 
mass spectrometry now mean that lower sample volumes are required for toxicological analysis 
[1,6,7]. This allows minimally invasive microsampling (i.e. < 100 µL) methods such as the use 
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of dried blood spots (DBS). This study presents the detection and quantification of 
benzodiazepines from dried blood spots (DBS) by UPLC-qTOF-MS. 
 
1.2 Benzodiazepines 
Benzodiazepines are sedative-hypnotic drugs commonly prescribed for anxiety, 
insomnia, and seizure management for conditions such as epilepsy. They are also used for an 
anesthesia and sedation for certain medical procedures [8]. There are close to 35 
benzodiazepines approved for clinical use. Although the different drugs vary in potency, 
absorption, half life, and metabolism, they have similar general structures and mechanisms of 
action [9-11]. The initial interest in the use of this class of drugs was the relatively quick 
effect and low toxicity [10]. All benzodiazepines have the same basic structure. The range in 
potency has helped in a wide range of cases as the clinical effective dose is variable across 
prescribed benzodiazepines and use can range from anxiety relief to sedation [9,11]. 
Benzodiazepine effects are subject to tolerance in the effects causing sedation, anti-
convulsant action and anxiolytic properties. These drugs are subject to dependence, and may 
have substantial abuse potential with many patients suffering difficult withdrawal [9-11]. Co-
administration with alcohol or other drugs has been observed [8]. Recently studies, such as 
one by Hoiseth et al. have examined the prevalence of new designer benzodiazepines in drug 
impaired driving and other criminal cases [12]. Of 77 cases where designer benzodiazepines 
were detected over a 3-year period, only 6 cases were absent of any other drug. There is a 
distinct lack of research about the blood concentrations of these new drugs and how they 
correlate to impairment. The ability to detect and interpret concentrations both older, 
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commonly prescribed, and newer, designer, benzodiazepines is crucial in driving impairment 
cases [12]. 
There are many methods available for the detection of benzodiazepines from whole 
blood and urine, as well as from hair. The most common methods appear to be liquid 
chromatography mass spectrometry (LC-MS), liquid chromatography tandem mass 
spectroscopy (LC-MS/MS), with some gas chromatography (GC) methods reported [1,12-
16]. Varied success had been achieved in quantitative analysis of benzodiazepines using 
GC/MS methods [1]. These compounds have been shown to be highly susceptible to thermal 
degradation and rearrangement, with varied reaction products produced in unpredictable 
patterns, limiting accurate application of GC/MS [1,13]. The variable nature of the potency of 
these drugs has complicated the choice of method, as sensitivity is required for those with 
high potency but resolution needs to be maintained with high concentrations of those with 
low potency [13]. Benzodiazepines also show a range of polar characteristics varying the 
behaviour of different species during extraction and chromatographic separation. This 
polarity also requires derivatization to induce nonpolar qualities before chromatographic 
separation [13,15]. LC/MS is less restrictive of chemical properties accommodating a wider 
range of polarities, molecular weights, and temperature dependence. High-pressure systems 
such as HPLC and UPLC have been introduced that allow higher resolution, and quicker 
analysis time [7,15,18-22]. The use of a quadrupole time of flight-mass spectrometer (qTOF-
MS) as a detector has increased in popularity. There is the potential to apply it to both 
screening and quantitative analyses. This method allows the determination of accurate mass 
and retention time as identifying features of a given unknown compound [17,19,20,22]. This 
can be combined with modes, such as MSE that alternates between low and high energy 
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ionizations to induce varying degrees of fragmentation to allow high-resolution measurement 
of the mass of both the parent ion and ion fragments [7]. Distinguishes between compounds 
with similar retention times and/or same molecular weight for confirmation of identity [7]. 
The measurement of exact mass has also been cited to decrease both the matrix effects and 
interferences as it allows reduction of noise from compounds of the same nominal mass 
[7,17,20]. Both solid phase extraction and liquid-liquid extraction have been reported for the 
sample preparation of whole blood suspected to contain benzodiazepines. This is required 
especially with small concentrations of analyte when efficient removal of interfering 
compounds is necessary [15,18,21]. The basic properties of benzodiazepines influence the 
extraction solvents and mobile phases used. The tendency is to use polar organic extraction 
solvents to remove the drug from the sample matrix along with the plasma proteins that bind 
with the benzodiazepines [23]. This allows high protein binding affinity to be overcome for 
benzodiazepines that tend to stay associated with plasma proteins [23]. There is also the 
tendency to use electrospray ionization in positive mode with acidic mobile phases when 
analyzing basic compounds as it has been shown to ionize most basic drugs; it appears to be 
the most widely used [15,19,20, 23]. The pairing of UPLC/QTOF/MS using ESI has the 
potential to be a good method for identifying and quantifying benzodiazepines. 
 
1.2.1 Pharamacokinetics and Pharamacodynamics of Benzodiazepines 
The main site of action for benzodiazepines is one of the main inhibitory receptors in 
the body: γ-aminobutyric acid, GABAA, receptors. In binding to these receptors they increase 
the inhibitory effect of GABA therefore increasing the permeability of the plasma membrane 
to chloride ions, allowing an influx into the cell and decrease in the action potential of the 
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neuron deactivating activity [8,10,24,25]. Benzodiazepines have a specific binding spot at the 
junction of the α and γ subunits on the receptor [24]. Although the exact mechanism is still 
not clearly understood, binding causes ion gates to open more frequently. They do not act 
directly on the GABA receptor to induce the effect but rather alter the shape by binding to the 
benzodiazepine binding spot to cause the increase in frequency of opening [25]. This action is 
what depresses the central nervous system. Two different forms of the GABA receptor have 
been found: the α-1-GABA receptor is connected to the sedative, memory, and 
anticonvulsant activity, whereas the α-2-GABA receptor is more linked to anxiety relief [10].  
The activity of benzodiazepines in maintaining the activation of GABA receptors for 
long periods of time prompts the body to compensate for this increase in inhibitory action to 
maintain homeostasis. This results in the development of tolerance, whereby the mechanism 
is not completely understood [26, 27]. The rate at which tolerance occurs is most likely 
linked to factors such as the type of benzodiazepine, dose, and route of administration [26]. It 
has been proposed that tolerance results from the conformational change of the GABA 
receptor induced by the binding of benzodiazepines being reduced over time so that that the 
drug does not cause the same effect at the same concentrations. It has also been reported that 
with repeated use there is a reduction in the number of receptors being produced in the body 
to regulate the increased inhibitory GABA activity produced by benzodiazepines [26]. 
Similar changes can also be induced by the presence of other drugs that enhance GABA 
activity such as ethanol and barbiturates. This allows for the development of cross tolerance, 
when having developed tolerance for compounds from one class may offer a degree of 
tolerance to another similarly acting drug [27]. 
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The most common route of administration for benzodiazepines is oral, but they can 
also be taken however the user chooses such as intravenously or intramuscularly [24]. There 
is a large variety in the properties of benzodiazepines based on the variable structure from 
addition of different functional groups to the common backbone. Lipid solubility is a variable 
factor that affects the rate of absorption and diffusion into the body [25,26]. Most tend to 
have a high bioavailability even when taken orally. Benzodiazepines with a higher 
lipophilicity have a quicker rate of absorption and distribute more within tissue. The duration 
of effect of these compounds and their bioavailability is also varied, and are grouped into 
short, intermediate, and long acting [25]. 
 A wide variety of cytochrome P450 enzymes are used for metabolism of different 
benzodiazepines, the main enzyme being CYP 3A [28]. These enzymes either hydroxylate, 
demethylate, or nitro-reduce to alter the structure to facilitate elimination from the body 
[10,28]. These metabolic enzymes are primarily found in the liver, but also occur in other 
tissues [28]. Many of these drugs have active metabolites that continue to affect the body, 
such as diazepam with its three active metabolites: nordiazepam, temazepam, and oxazepam 
[10]. There is a second pathway in benzodiazepine metabolism where diphosphase 
glucoronosyltrasnferase adds a glucoronide to the metabolite or drug to aid in metabolism 
[28]. This is seen in 3-hydroxybenzodiazepines such as lorazepam and oxazepam, which are 
not acted on by CYP enzymes [29].  
Benzodiazepines are commonly used in combination with many different drugs, 
which produces a high potential for drug interaction. This action can either inhibit or enhance 
the rate of metabolism of the drug or the effect of the drug. As the metabolism of these drugs 
is mediated largely by CYP enzymes, there is a potential for drug interactions with other 
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classes of drugs [10,30]. Some include certain antidepressants such as tricyclic anti-
depressants and selective serotonin re-uptake inhibitors (SSRIs), opiates, antipsychotics, and 
alcohol. The interaction of benzodiazepines with other drug classes is entirely dependent on 
their route of metabolism [30]. For example, fluvoxamine, a SSRI, inhibits CYP3A and 
CYP2C19, affecting the metabolism of benzodiazepines such as alprazolam and diazepam 
that are oxidized and metabolized by CYP3A4. SSRIs also interact with the enzyme and slow 
the action, decreasing the rate of metabolism and therefore the extending the time the drug is 
in circulation in the body [31]. Co-administration of fluvoxamine and alprazolam resulted in 
a significant increase in plasma alprazolam concentrations and an extended half-life [31]. 
Pharmacodynamic interactions have also been proposed, such as an enhancing effect of 
benzodiazepines on opioids, and vice versa [32]. The effect of benzodiazepines on the delta 
opioid receptor, an important site of action of opiates, was found to mediate the anxiolytic 
effect of benzodiazepines as well, indicating a potential explanation for the combined use of 
these drugs [33]. An additive effect from the action of both benzodiazepines and opiates on 
this receptor is experienced when taken together. An additive effect of not only the anxiolytic 
properties of benzodiazepines but also the general analgesic effects of opioids has also been 
suggested [32,33].  
 
1.2.2 Benzodiazepines and Impairment of Faculties Required for Safe Driving 
Benzodiazepines are commonly prescribed to the general population for their effects 
as sedatives and hypnotics. They have also been regularly abused [8]. An obvious concern is 
the ability of those individuals taking them both therapeutically or recreationally to drive. 
There has been a noticeable increase in drug impaired driving in the last two decades, with a 
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high frequency of benzodiazepines being observed [34]. In a recent study of fatal motor 
vehicle accidents in Ontario, benzodiazepines were one of the most commonly encountered 
compounds after cannabis and alcohol [35]. This was also presented in an Australian study 
from 2016, where benzodiazepines were detected in 7.0% of fatally injured drivers from 
2000-2013 [36]. The odds ratio was given to be 5.2 although stated as not statistically 
significant due to low number of incidences [36]. There has also been a high incidence of 
benzodiazepines in combination with other substances observed, for example in Norway in 
1995; of cases where benzodiazepines were found in suspected impaired drivers, 92% 
included other substances of which 73% involved alcohol [34]. The impairing effects of 
benzodiazepines have been well studied. A well-correlated relationship after an acute dose 
between the effect of benzodiazepines and the decline of psychomotor and cognitive ability 
has been shown [36-41,43]. Impairment has been shown to have a dependence on blood drug 
concentration that was also determined to be present in chronic administration [41]. Multiple 
studies under controlled conditions have found impairment to visual perception, information 
processing, coordination reaction time, and memory [36-41,43]. A recent retrospective study 
found that an observable decrease in performance in common field sobriety tests focused on 
balance control and motor function correlated to blood concentration whereas pupil size, 
nystagmus, and orientation of time and place could not be correlated [39]. A meta-analysis 
study compiled the data from clinical and toxicological data and established the range of 
concentrations across which people have been found to be impaired. These values are seen in 
Table 1.1 for the drugs of interest in this project [42]. There is a distinct overlap observed 
between the therapeutic and the impairment ranges. Overlap of therapeutic and impairment 
ranges is a common observation, according to a study in which blood concentrations of 
	  	   9	  
lorazepam and determination of impairment after detention in Washington were analyzed 
[43]. The mean concentration of individuals found impaired by lorazepam alone was 0.051 
mg/mL within the therapeutic range of 0.018 mg/L to 0.240 mg/mL [43]. Therefore 
individuals taking benzodiazepines at therapeutic doses may still exhibit signs of impairment, 
but there is also the consideration of tolerance. A study from Norway found that there is a 
direct relationship between the increase in impairment and an increase in blood 
benzodiazepine concentration [38]. There has been disagreement about the ability to establish 
a set blood concentration above which individuals are impaired when taking benzodiazepines 
especially when considering that users are susceptible to development of tolerance to this 
drug class [44]. However, the authors of the latter study believed they presented data 
supporting potential for legal limits as the odds ratio of being determined as impaired by 
benzodiazepines increased across a range of 4 levels from therapeutic to highly elevated 
blood concentration ranges [38]. There is still research to be done regarding a limit above 
which most individuals are impaired, but it has been extensively shown that benzodiazepines 
do cause impairment of skills required for driving [36-41,43]. Currently individuals undergo 
field sobriety tests to establish reasonable and probable grounds to believe an individual is 
impaired before samples of are taken of blood, urine, or oral fluid to measure the 
concentration of the impairing substance. A recent study published in 2016 looked at the use 
of point-of-contact oral fluid drug screening devices as a presumptive test to identify and 
determine recent drug use at detention in suspected drug impaired driving cases [45]. This 
study showed acceptable performance with certain drugs of abuse, however the average 
sensitivity of the benzodiazepine tests was 0.592, indicating that true-drug positive 
individuals were only identified 59.2% of the time [45]. This result suggests difficulties in 
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establishing recent exposure to benzodiazepines using oral fluid, further supporting the use of 
blood as the sample of choice for drug impaired driving cases. Collection of blood must be 
done by a medical practitioner or qualified technician [5]. A method that could be used to 
mitigate this need while reducing the delay between incident and sampling would be 
beneficial to establishing concentration at the time of detention. It would be advantageous to 
confirm impairment established by standard roadside tests closer to time of detention.  
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Table1.1: List of nine benzodiazepines and metabolites of interest with their half-life, 
common dose, therapeutic drug concentration range and impairing drug concentration range 
[42]. 
Drug of Interest Half life 
(hours) 
Common 
Dose (mg) 
Therapeutic Blood 
Concentration 
(ng/mL) 
Impairing Blood 
Concentration 
Range (ng/mL) 
Diazepam 50-120 4-40 100-800 8-2500 
Oxazepam 6-20 30-120 200-1500 6-10000 
Temazepam 6-25 7.5-30 20-900 ** 
Nordiazepam† ** N/A 20-800 6-10000 
Lorazepam `10-40 2-10 3-250 <10-630 
Alprazolam 6-20 0.5-10 5-55 20-650 
α-hydroxyalprazolam† ** N/A <10% of alprazolam 
concentration 
** 
Clonazepam 20-60 1.5-20 20-80 15-125 
7-aminoclonazepam† ** N/A ** 11-68 
**unable to find the information 
† metabolite not prescribed on its own as medication 
N/A not applicable as a metabolite not prescribed independently; no dose information 
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1.3 Dried Blood Spot Analysis 
Techniques utilizing dried blood spots (DBS) have been used since the early 1960s, 
initially used in neonatal blood screening for metabolic disorders. It is an alternative to 
drawing venous blood [46-48]. Analysis of DBS extracts has been used to detect a wide 
variety of biological molecules such as DNA, various amino acids, other organic acids, 
proteins, and hormones [47,48]. Studies have also been published showing results from the 
analysis of smaller molecules such as drugs and other toxins. Although initially the interest 
was focused within neonatal testing there has been an increase in interest in DBS within 
fields such as therapeutic drug monitoring and toxicology [46-54]. The principle behind the 
technique is fairly simple; the heel or finger of the individual being tested is pricked and a 
small quantity of blood is removed and placed onto a card with distinct areas to spot the 
blood that will be left to dry and then that spot can be analyzed. The card is usually made up 
of a cellulose material but the composition can vary between companies such as the presence 
and nature of added preservatives [47,48].  
In order for this to be advantageous for use in forensic toxicology, sensitive analytical 
methods able to detect the small amounts of drug present in the smaller volumes of blood 
collected using DBS, and with a high level of accuracy need to be available. With the 
continual development of separation and detection methods such as MS and MS/MS the use 
of DBS within this discipline has become more plausible [49]. These detection methods are 
commonly attached to instruments performing HPLC or UPLC to separate the various 
compounds in a given sample before they reach the detector. Many methods have been 
developed and validated for quantifying individual drug and multidrug mixes from DBS 
extraction analyzed using MS/MS [14,46-50,52,54-56]. More recent research has identified 
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extraction and screening methods for larger groups of drugs with varying properties to 
optimize the amount of drugs they can detect in one run. A recent study proposed a method of 
identification and quantification of 64 psychoactive drugs from multiple classes extracted 
from DBS using UPLC-MS/MS [55]. The authors were successful in meeting the standards 
required for reliable quantitative methods with precision and accuracy below a coefficient of 
variation below 20%. They were able to apply this method to real case samples detecting 
most of the drugs reported to be taken by the individual and identified by immunoassay [55]. 
A comparison of concentration determined with DBS compared to venous blood 
concentration was not reported; an important consideration in correlating DBS to possible 
effects of the drug [55]. Another method recently developed used LC-MS/MS to optimize 
detection and quantification of a large mix of benzodiazepines, their metabolites, and a z-
drug from DBS [14]. They spotted 30 µL of blood onto the card before extracting with a 1:1 
volume to volume methanol-acetonitrile mix before vortexing for 1 minute. All standard 
curves reported coefficient of determinations, R2, of 0.99 with precision and accuracy 
measurements all below the 20% requirement from the Scientific Working Group of 
Toxicology (SWGTOX) for quantitative analytical methods [14]. These are all positive 
results for a reliable method to determine the amount of drug in the sample. A concern in this 
study was the high amount of matrix effects that were reported, with most values above the 
20% cutoff recognized by SWGTOX [14,46,54]. However, a good starting point for 
successful methods that allow the development and simplification of extraction and 
quantification of benzodiazepines from DBS was found [14]. A newer method of detection, 
UPLC quadrupole time of flight mass spectrometer (qTOF-MS), has more recently been 
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proposed for the analysis of small molecules but presents minimal research available in 
applying this method to DBS analysis [17,20,21,46,54,57].  
 
1.3.1 Advantages and Disadvantages 
The emergence of interest within forensic toxicology communities in using DBS is 
based on the many advantages that have been associated with this technique. One of these 
advantages is a less invasive collection technique [48]. The collection of a blood sample from 
living individuals is associated with many legal considerations to respect the basic rights of 
the individual, making collection of venous samples a more laborious process as qualified 
individuals trained in drawing blood must be found. This prolongs the time the individual is 
waiting to give the sample. Over this time, metabolism of the compound of interest will 
continue to occur within the individual. This potentially reduces the interpretative value of 
the sample, as the blood drug concentration level is lowered and less representative of the 
initial concentration at the time of detention [47-49]. DBS may allow law enforcement to 
overcome this issue. Another important advantage is the stability of the compounds once 
spotted on the card matrix. There have been studies that test the stability of drugs including 
drugs such as cocaine and benzodiazepines that are structurally prone to degradation in 
aqueous environments [50,51,55,58,59]. The integrity of the drugs appears to be well 
maintained over prolonged periods of time. In one particular study concerning cocaine and 
benzodiazepines, three different storage temperatures were compared. At all temperatures 
there was less than a 20% reduction in the concentration after a month, with less than 10% 
reduction in the freezer for all drugs and in the refrigerator for all benzodiazepines when 
compared to initial concentrations of samples spotted on DBS [58]. A limitation to this study 
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was they did not compare degradation between whole blood vials and DBS to show a 
difference in degradation percent. Testing also did not continue beyond a month. The 
precision of the method was within a range of 1.6%-18.3% for intra- and interday 
experiments. However, because of this, DBS have been suggested to offer a faster and 
simpler way to obtain a blood sample, as it only requires a finger prick and the cards to can 
be shipped without refrigeration. There is also a simplification in storage and transportation 
of DBS compared to blood vials [47]. 
Another advantage is the small volumes that can be collected. This was originally a 
limitation but now with improvement of the sensitivity of the instrumentation this is viewed 
as beneficial when little sample is available and also allows the use of the less invasive 
technique discussed above. The volumes spotted on the card for toxicological studies range 
from 10-40 µL. Multiple study results have been published using DBS methods that satisfy 
all the requirements for quantitative analytical methods using small volumes within this range 
[14,46-50,52,54-56].  
Although there are clear advantages, there are also some limitations to consider in 
terms of this method of collection that may impair the ability of a researcher to determine 
accurate and reliable analyte concentrations. The small volume spotted onto the card 
introduces sources of error due to variation in properties such as blood viscosity, hematocrit, 
drug distribution, spotting technique, and the card matrix itself [47,48]. This introduces the 
uncertainty of the distribution of the drug throughout the card. Even if the extract volume 
added to the card is controlled, how much does the determined concentration deviate from the 
venous concentration. A uniform distribution of the drug would be ideal but that is not 
always the case [60-62]. This has raised a concern mostly in cases where it is not the entire 
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blood spot being punched out but rather a small portion. Solutions have been proposed for 
this problem. One is punching an area that encompasses the entire spot and controlling the 
volume that is being added to the card, and the other is precutting the card before spotting it 
with a particular volume [63,64].  The precut technique showed results that were comparable 
to the common method of punching out a known area of the spot but without the 
mathematical equation that is necessary when using the more common method to determine 
the total blood volume of the spot itself [64]. Published studies removing the entire spot have 
reported results that were comparable to results taken when a sample of the spot is taken [63]. 
This was a proposed method used in a paper by Youhnovski et al. that was comparing a new 
pre-cut dried blood spot technique to the conventional smaller diameter sampling. The 
precision and accuracy of the results were all within the required parameters that ensure a 
method that is adequate for reliable quantification [64]. Therefore there are two simplified 
approaches that require no mathematical equation step to determine spot volume when back-
calculating concentration.  
Another limitation that relates to a disruption in the equal distribution of drug 
throughout the spot that would interfere with DBS quantification methods is the effect of 
hematocrit [47,49]. Hematocrit is the percentage of erythrocytes in a given volume of blood. 
This crucial property of blood is directly related to the viscosity of blood causing it to have a 
direct effect on the diffusion through the card. Within humans there is a normal range of 
0.37-0.51 for adults but can reach between 0.2 and 0.8 and above in cases of disease [47]. A 
higher percentage of red blood cells may restrict movement of the blood into the card and 
therefore distribution. This may also have a significant effect when the drugs are highly 
protein bound, such as with benzodiazepines, causing the drugs to be concentrated in areas 
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where the erythrocytes remain, and not where the serum may have spread beyond; this would 
most likely also have a profound effect with a lower hematocrit [16, 65]. This also offers a 
challenge in interpretation as drugs that are more highly bound to erythrocytes may show an 
artificially high concentration compared to those with lower hematocrits, as more drug will 
be concentrated on the spot [65]. Therefore this is an important parameter to test 
experimentally. As previously mentioned, the study by Youhnovski et al. showed an increase 
in the bias of the measured quantity of drug at the higher and lower ends of the range of 
variation in humans [64].  A study that was conducted to quantify dexamethasone in DBS 
showed that there was a difference across different hematocrits in quantification but within 
the normal range of adults the accuracy did not change over 20%; it appeared that the 
extremes in variation are where the problems would lie [66]. Similarly, effect of hematocrit 
on 25-hydroxy vitamin D2 and D3, found that there was no significant difference in their 
ability to measure the concentration of the compound from DBS across a range of hematocrit 
from 0.4-0.6 [67]. Although comparable results were found with the alternate spot sampling 
methods, in the study by Leuthold et al. a loss of accuracy was determined to occur at 
hematocrit levels that deviated from the normal range of humans [61]. 
A major limitation in terms of using DBS in forensic toxicology to assess impairment 
at the time that the sample was taken is the correlation of venous blood, the preferred matrix 
allowing the best estimation of drug concentration, and capillary blood [48]. In the simplified 
sample method that is highlighted, an advantage of DBS is the ability to collect the sample 
from a finger prick which will involve the collection of capillary blood rather than blood 
directly from the vein [47]. Possible problems may arise from the tendency of capillary blood 
to have a higher hematocrit than venous blood [47]. Before a quantification method can be 
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interpreted reliably it will have to show that the concentrations that are being determined in 
capillary blood correlate to venous blood, so that interpretation could be made regarding the 
impairment of the individual. If not, the method may only serve as an identification method, 
only being able to confirm if the compound was present or not in the blood [48]. An 
experiment with this goal was conducted in a study seeking the correlation of capillary blood 
cocaine concentrations and plasma blood concentrations [51]. It was found that the 
concentrations correlated well after hematocrit was taken into effect, as it was comparing 
plasma to whole blood, allowing interpretation of cocaine concentrations in venous blood 
from DBS [51]. Recent research has looked to optimize the advantages and minimize the 
disadvantages of DBS. One paper from Saussereau et al. looked to minimize these effects as 
well as simplify the procedure by using on-line sample cleaning methods where the 
extraction solvent is immediately injected into an on-line system after extraction [68]. This 
method measured a selection of common illicit drugs. Using this system the hope is to allow 
a quick and simple process that further eliminates transfer steps and reduces the potential for 
contamination. Using this on-line method, precision and accuracy for all drugs had a relative 
standard deviation and bias measurements below 20%. The recoveries obtained for the group 
were all above 75% at a low concentration of 20 ng/mL [68]. Within real samples a 
coefficient of determination was 0.98 and above [68]. Results such as those above show 
potential for the development of accurate and precise methods that allow the quantification of 
drugs from DBS, with considerations of hematocrit and capillary-venous blood correlations 
needed for proper interpretation of results.  
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1.3.2 Forensic Relevance of DBS 
It is evident from the current state of research within drug detection and quantification using 
DBS methods that this has a high potential for use in forensic toxicology. Considering the 
advantages of a less invasive sampling procedure and small sample volumes as well as 
stability of the compounds within the matrix, DBS lends itself well to be considered as a 
road-side collection technique. There has already been a wide range of success with 
identifying drugs from a wide range of classes from antemortem and postmortem blood 
[14,46-50,52,54-56]. Currently, road side tests to measure the level of impairment due to 
drugs in Canada is limited to psychomotor tests, and the collection of biological samples 
required for confirmation of the presence and concentration of the drug happens later, after 
qualified personnel has been found to draw blood [5]. This long period between detention and 
the sampling of the blood; does not offer a complete idea of the individual’s level of 
impairment when pulled over, as the body has had time to metabolize more of the drug, 
producing a lower concentration of the drug at the time of sampling. The continued 
development of extraction methods for different drug classes, with different detection 
techniques such as UPLC-MS/MS and UPLC-qTOF-MS to include a wider range of drugs 
that can be identified as well as inclusion of on-line methods to speed up the process also 
offer the potential for more efficient and quick analysis of impaired driving cases. 
 
1.4 Main Objective of Study 
The main objective to be reached in this study was the development and validation of a 
screening method for the detection of nine benzodiazepine and benzodiazepine metabolites 
from dried blood spots that could also function to quantify the identified analyte. The aim 
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was to develop a simple extraction method followed by detection with UPLC-QTOF-MS. 
The nine compounds were drugs commonly prescribed from this class worldwide. The list 
consists of diazepam and its three metabolites, temazepam, oxazepam, and nordiazepam, as 
well as lorazepam, alprazolam, its metabolite α-hydroxyalprazolam, clonazepam, and its 
metabolite 7-aminoclonazepam. Being able to detect and quantify the drugs at blood 
concentrations relevant to impairing blood concentrations determined through both 
experimental and retrospective studies was important. A number of parameters were modified 
in regards to the sample preparation and extraction method applied to the dried blood spots. 
This was necessary to optimize matrix effects present due to the chromatography method, 
within the ±20% range required by the SWGTOX acceptable for quantitative methods, while 
maximizing recovery of the analytes of interest. The precision, determined through the 
calculation of the coefficient of variation, was also required by SWGTOX to be within 20% 
for methods acceptable for quantitative analysis. If these parameters were not met, an 
alternative semi-quantitative analysis would be proposed. 
 
 
 
 
 
  
	  	   21	  
CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Chemicals and Materials 
All benzodiazepine standards (diazepam, lorazepam, oxazepam, alprazolam, 
clonazepam, nordiazepam, temazepam) and benzodiazepine metabolites (7-
aminoclonazepam, α-hydroxyalprazolam) at a concentration of 1.0 mg/mL as well as 
deuterated internal standards (diazepam-d5, oxazepam-d5, alprazolam-d5, nordiazepam-d5, 
7-aminoclonazepam-d4, α-hydroxyalprazolam-d5) at a concentration of 100µg/mL were 
obtained from Cerilliant (Round Rock TX, USA). LCMS-grade methanol, acetonitrile, and 
water used in sample preparation, extraction, and separation steps were purchased from 
OmniSolv Inc (Charlotte, NC, USA). LCMS- grade formic acid and ammonium formate were 
purchased from Fisher Chemical(Fair Lawn, NJ, USA). The dried blood spots cards were 
Whatman 903TM Protein Saver DBS cards (GE Healthcare Ltd, Cardiff, UK). A 1/2” hole 
punch (EK Success Ltd, US) was used. All dried blood spots were made using sterile, drug 
free sheep blood supplied by the Niagara Police Services (Canada).  
 
2.2 Dried Blood Spot (DBS) Preparation 
Benzodiazepine stock solutions were prepared at concentrations of 40µg/mL, with 
diazepam, clonazepam, nordiazepam, oxazepam, temazepam, alprazolam, and α-
hydroxyalprazolam prepared in methanol, and lorazepam and 7-aminoclonazepam prepared 
in acetonitrile. A stock mix of all benzodiazepine standards was prepared to a concentration 
of 2.86 µg/mL per drug. This mix was used to make all calibrators. Stock solutions of internal 
standards were prepared to a concentration of 4 µg/mL with diazepam-d5, oxazepam-d5, 
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nordiazepam-d5, alprazolam-d5, and α-hydroxyalprazolam-d5 prepared in methanol and 7-
aminoclonazepam-d4 prepared in acetonitrile. The stock solutions were combined to produce 
a final concentration of 0.5 µg/mL per drug. Consideration of therapeutic and impairment 
ranges of the benzodiazepines under investigation led to the following blood concentrations 
to be assessed for all method development experiments: 15 ng/mL, 150 ng/mL and 450 
ng/mL. Appropriate volumes of 2.86 µg/mL benzodiazepine mix were combined in clean test 
tubes with 1 mL of blood to produce spiked blood samples of each desired concentration. The 
solution was inverted and vortexed to ensure uniform distribution.  
For method validation, concentrations ranging from 0 ng/mL to 500 ng/mL were 
produced. Spiked blood standards for curves were prepared by serial dilution. Sufficient 
aliquots of benzodiazepine mix was measured out and added to 2 mL of blood to make a 500 
ng/mL sample, which was inverted and vortexed. A serial dilution followed to make 250 
ng/mL, 125 ng/mL, 62.5 ng/mL, 31.3 ng/mL, 15.6 ng/mL and 7.8 ng/mL calibrator solutions.  
Preparation of DBS was performed the day before extraction was performed. Aliquots 
of blood (20 µL), both spiked, benzodiazepine standards and drug-free controls, were spotted 
onto Whatman 903TM cards using a 20 µL micropipette (Drummond Scientific Co. Broomall, 
PA, USA). Blood samples were spotted in triplicate for controls and calibrators. Samples 
were dried overnight under ambient conditions for a minimum of 12 hours between spotting 
and extraction. 
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2.3 Method Development 
                 Before proceeding with method validation steps and extracting target compounds 
from authentic samples, there are parameters that had to be analyzed and optimized. These 
included assessment of solvent and spot agitation methods to optimize extraction time, 
optimization of extraction solvent, method of internal standard application, sample clean up 
steps (protein filtration and different solvent systems) to optimize matrix effects and 
recovery, and reconstitution solvent. Three solvent-spot agitation methods were assessed: 
vortexing, sonication, and rapid agitation utilizing a Tissuelyzer® (Qiagen). Four extraction 
solvents were tested: methanol; 1:1 v/v methanol:acetonitrile; 1% formic acid in methanol; 
and 1% formic acid in 1:1 v/v methanol:acetonitrile. Acetonitrile was assessed as an 
extraction solvent in preliminary experiments, but recovery was sufficiently poor, that it was 
not tested further (data not shown). Internal standard addition methods tested included adding 
the internal standard mix to the spot on the card before removing the spot; removing the spot 
and placing in a clean test tube before adding the internal standard mixture. Both methods 
were tested either immediately or 2 hours post-addition. Adding the internal standard directly 
to the extraction solvent was also tested. Inclusion of protein filtration, using Clean Screen 
FASt® 96 well plates (100 mg, United Chemical Technologies, Bristol, PA) for sample clean 
up, was tested to improve matrix effects. To optimize recovery and matrix effects for this 
step, four different solvent systems were tested: extraction in 1:1 methanol:acetonitrile; 
extraction in 1:1 methanol acetonitrile with 1% formic acid; extraction in 1:1 
methanol:acetonitrile with addition of 1 mL of acetonitrile before filtration; and extraction in 
1:1 methanol:acetonitrile with addition of 1 mL of acetonitrile with 1% formic acid before 
filtration. To improve recovery, reconstitution in mobile phase A was compared to 
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reconstitution in 1:1 v/v water:acetonitrile.  Analyte stability within the card was assessed at 
1, 2, 7, 14, and 28 days post-spotting at both ambient temperature and 4°C. Hematocrit 
effects were measured using a hematocrit range of 20-70%. Accuracy, precision, and 
concentration dependence were assessed over a concentration range of 0-500 ng/mL 
benzodiazepine mix in blood. Matrix effects, recovery, accuracy, and precision were all 
measured and optimized to meet parameters outlined in SWGTOX guidelines.  
 
2.4 Sample Preparation 
 Each spot was removed using a ½” hole punch after waiting the minimum dry time of 
12 hours and placed in a clean test tube. Internal standard mix (20 µL) was then added 
directly to each spot, using a 20 µL microdispensor. Methanol:acetonitrile (1 mL of 1:1 v/v) 
was added directly to the test tube, completely immersing the spot. This was sonicated for 30 
minutes. The extraction solvent was removed from the spot, and placed in a clean test tube, 
where 1 mL of acetonitrile was added to the test tube. Vortexing was used to mix the 
solution. Using a Pasteur pipette, the extraction solvent was introduced into one of the 96 
wells of the Clean Screen FASt plate to filter. The filtrate was transferred to a clean test tube 
and evaporated to dryness at 70°C by vacuum centrifugation and reconstituted in 200 µL of 
H2O:ACN (1:1 v/v). The reconstituted filtrate was transferred to micro-centrifuge tubes 
(VWR Radnor, PA, USA) and centrifuged at 13,000xg for 10 minutes at 4°C. The 
reconstituted extract was then placed in a clean insert and vial to prepare for injection for 
analysis by ultra-performance liquid chromatography-quadrupole time of flight-mass 
spectroscopy (UPLC-qTOF-MS). 
 
	  	   25	  
2.5 UPLC- qTOF-MS System 
Analysis of DBS extracts, injected at a volume of 2 µL, was performed using an 
Acquity UPLC equipped with a Xevo-G2-XS qTOF-MS (Waters, Milford, MA). The UPLC 
employed a Waters Acquity HSS C18 column (150 mm×2.1 mm, 1.8 µm particle diameter). 
The elution gradient, Table 2.1, was used fro UPLC separation. The UPLC and qTOF MS 
conditions are summarized in Table 2.1. Mobile phase A was 5mM ammonium formate in 
1% formic acid in LCMS grade water. Mobile phase B was 1% formic acid in LCMS grade 
acetonitrile (OmniSolv Billerica, MA, USA).  
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Table 2.1 Settings under which DBS extracts were sampled, separated and analyzed under 
using Waters AQUITY UPLC equipped with a Xevo-G2-XS qTOF-MS. 
Chromatography 
 
Liquid Chromatography system Waters ACQUITY UPLC 
Column Waters ACQUITY UPLC® HSS C18 (2.1 
mm x 150 mm, 1.8 µm) 
Column Temperature 50 °C 
Injection Volume 2 µL 
Solvent A Water with 5mM ammonium formate, 0.1% 
formic acid  
Solvent B Acetonitrile with 0.1% formic acid 
Gradient 0-1 min 20% solvent B 
1-2 min 20-30% solvent B 
2-4.5 min 30-65% solvent B 
4.5-7 min 65%-70% solvent B 
7-8.5 min 70-77 % solvent B  
8.5-9 min 77-95% solvent B 
9-9.5 min 95-20% solvent B 
9.5 -11 min 20% solvent B 
Total Run Time 11 min 
Flow Rate 0.400 mL/min 
Mass Spectrometry 
 
Mass Spectrometer Waters XEVO-G2-XS 
Ionization Mode Electrospray +ve 
Capillary Voltage 0.80 kV 
Cone Voltage 40 kV 
Desolvation temperature 500 °C 
Desolvation Gas  1000 L/h 
Source temperature 150 °C 
Data acquisition TOF MS 
Mass range 50- 601 Da 
Lock spray Leucine Encephalin  
m/z= 278.1171  
Sensitivity Mode  
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2.6 Extraction Time Study 
Three different spot-solvent agitation methods (vortexing, sonication, and rapid 
agitation (Tissuelyzer®)) were compared to select a method that would optimize extraction 
time, recovery, and throughput. The choice of agitation method was the first parameter 
determined for this study. DBS were prepared as outlined in section 2.2, at 0, 15, 150, and 
450 ng/mL. Internal standards were added to each spot just prior to extraction. Methanol (1 
mL) was added to each clean test tube and used as the extraction solvent for this preliminary 
experiment. A set of each concentration in triplicate was extracted over a 60-minute period 
using each of the three spot-solvent agitation methods. The entire volume of extraction 
solvent was removed and transferred to a clean test tube after 5 minutes and replaced with 
fresh methanol (1 mL). This was repeated at 10, 15, 30, 45 and 60 minutes. The extraction 
solvent from each time point was then evaporated to dryness at 70°C by vacuum 
centrifugation, reconstituted in 200 µL of MeOH and then centrifuged at 13,000xg for 10 
minutes at 4°C. Analysis of each set of time points for all concentrations using each spot-
solvent agitation method followed the procedure described in section 2.5 to observe the 
extraction of the analytes of interest over time. 
 
2.7 Matrix Effect and Recovery Measurements 
To develop the final method that was used in producing, extracting and analyzing the 
DBS for benzodiazepines, a number of conditions for each step of the method were tested. 
The performance of each of these conditions was assessed based primarily on the calculated 
matrix effects and recovery. Matrix effects and recovery were measured during method 
development for extraction solvent comparison, addition of protein filtration, comparison of 
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solvent systems for protein filtration, and reconstitution solvent. To measure matrix effects 
and recovery samples spiked pre-extraction and post-extraction were required as well as neat, 
matrix free, standards. Post-extraction spiked samples were produced by adding drug to drug-
free DBS extract at concentrations corresponding to those expected in extracted samples, 
presuming 100% extraction efficiency of both compounds of interest and internal standard. 
Extraction is achieved by following the same procedure as that of the pre-spiked samples. 20 
µL drug-free aliquots were produced in triplicate on Whatman 903TM cards. No internal 
standard was added to the post-extraction spots prior to extraction. Spiked post-extraction 
samples were produced by reconstituting the matrix evaporated to dryness in 200 µL of 
reconstitution solvent prepared to concentrations expected with 100% extraction efficiency. 
After the post-extraction addition of the benzodiazepine mixture and internal standards, the 
same procedure was followed as with the pre-spiked, with centrifugation at 13,000xg for 10 
minutes at 4°C. A neat standard, of the expected concentration, if 100% of the drug was 
extracted, without matrix, is required. This is prepared using the reconstitution solvent and 
adding the necessary aliquot for the desired concentrations corresponding to 100% of each 
analyte being obtained at the end of the procedure. This is added to a clean vial and injected 
directly. Neat standards require no extraction step or sample preparation steps as no matrix is 
introducing into these samples. Comparison of neat standard samples to pre-spiked samples 
allows quantification of matrix effects. Comparison of pre-spiked and post-spiked samples 
allows calculation of recovery. 
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2.8 Analyte Stability in DBS 
Stability of the benzodiazepines of interest in this study was assessed in dried blood 
on the Whatman 903TM card over a 1-month period at both ambient temperature and 4°C. 
DBS were prepared using the procedure outlined in Section 2.2 at concentrations of 0, 15, 
150, and 450 ng/mL. Spots were prepared in triplicate at each concentration and analyzed 
after 1, 2, 7, 14, and 28 days, at each temperature. All spots, both for the ambient temperature 
group and the 4°C group, were left overnight at ambient temperature to allow the blood to 
dry. The cards dried for 24 hours were analyzed after this step as the base measurement, 
represented as the day 1 measurement. All other spots were separated into clean plastic bags 
grouped by concentration, sampling time and storage temperature. All bags were sealed and 
remained sealed until analysis. The samples at ambient temperature were all placed in the 
same fume hood where they remained undisturbed until sampling. All samples at 4°C were 
placed within the same refrigerator all in the same general area, where they remained until 
sampling. At each time interval all spots were subjected to the same extraction and analysis 
procedure. Extraction followed the method described in Section 2.4 and analysis as described 
in Section 2.5.  
 
2.9 Hematocrit Effect 
The effect of different hematocrit levels on measured results was assessed. A range of 
20-70% was chosen to cover both a healthy range for humans and hematocrit changes seen 
along with disease. This was achieved by separating the components of drug-free whole 
sheep blood using a clinical centrifuge (VWR, Radnor, PA, USA) at 5000xg for 15 minutes 
in clean glass test tubes. The supernatant, plasma component, was removed and the pellet 
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consisting of red blood cells was set aside for testing, this was repeated until the volume of 
red blood cells satisfied the aliquots needed to make 1 mL of each hematocrit to be tested. 
Using an adjustable 1 mL microdispensor (Drummond Scientific Co. Broomall, PA, USA), 
sufficient red blood cells were added to clean test tubes to make 1 mL of each hematocrit 
being tested (20%, 35%, 45%, 55%, 70%) at 4 analtye concentrations (0, 15, 150, and 450 
ng/mL). The remainder of each 1 mL volume was completed with physiological saline, 0.9% 
NaCl in LCMS grade water. The benzodiazepine mix was then added to make one of each 
concentration at each hematocrit level. Each mixture was vortexed and inverted thoroughly to 
ensure uniform distribution of the red blood cells and the benzodiazepine mix. Each 
hematocrit and concentration pair were spotted (20 µL) in triplicate onto the Whatman 903TM 
card and left to dry overnight at ambient temperature. They were then extracted and analyzed 
as described in Sections 2.4 and 2.5. 
 
2.10 Autosampler Stability 
The stability of the benzodiazepines of interest in this study was also assessed over a 
36-hour period within the autosampler of the instrument. The autosampler is a part of the 
Waters AQUITY UPLC, and the chamber was set to maintain a constant temperature of 
10°C. A set of concentrations, 15.6, 125, and 500 ng/mL were produced using the procedure 
outlined in Section 2.2 run with the final procedure determined from method development. 
Samples were run at 0, 12, 24, and 36-hour time points. The injections were made from the 
same sample vials, and were used to assess the stability of the drugs within the reconstitution 
solvent in the autosampler if samples were to remain in the chamber for an extended period 
of time before analysis.  
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2.11 Analysis Procedure 
Identification of analytes was determined using the QuantLynx® software (Waters, 
Milford, MA). Using the retention time and accurate mass of each benzodiazepine of interest 
and corresponding internal standard, the software identified and calculated the peak 
integration. For each step of method development the peak integration was determined at a 
mass resolution of 0.05 Dalton (Da) from the specified accurate mass of each analyte. Mass 
resolution was reduced to 0.005 Da for identification of the compound and 0.01 Da for 
quantification from the specified accurate mass for all method validation steps. To correct for 
variation in conditions of each run, a response ratio was calculated. The analyte response 
ratio was calculated as follows: 
 
Response Ratio (RR)= !"#$  !"#!  !"#$#%&'(!"#$  !"#!  !"  !"#$%"&'  !"#$%#&% 
 
Response ratio was used for comparison of each of the different parameters that were 
assessed during method development and was the value used to calculate accuracy, and 
precision for method validation. The different parameters of each step of method 
development were assessed based on precision (assessed by the calculated coefficient of 
variation), matrix effects, and recovery. As outlined in the SWGTOX guidelines, coefficients 
of variation that exceed 20% do not fit the precision standard for good methods, therefore 
sample measurements must not vary more than 20% from the calculated mean of the sample. 
Coefficient of variation was calculated using the following equation: 
 
Coefficient of variation (CV) = !"#$%#&%  !"#$%&$'(  !"  !!!"#$  !!   ×  100% 
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Matrix effect is a required measurement when using LCMS. By SWGTOX 
guidelines, all matrix effects must be ±25% for a quantitative method. This was measured as 
described in Section 2.7. The value was calculated using the equation: 
 
Matrix Effects = !"#$  !"#$%&#'()  !"#$%&  !!!"#$  !"#$%#&%  !!!! ×  100% 
 
In order the optimize each step and assess the amount of each drug for each condition tested, 
recovery was also calculated using response ratios calculated using the integrated peaks of 
the drugs of interest and their corresponding internal standard. The value of recovery was 
determined using the equation: 
 
Recovery= !"#  !"#$%&#'()  !"#$%&  !!!"#$  !"#$%&#'()  !"#$!!  !!×100% 
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CHAPTER 3: RESULTS 
3.1 Method Development 
3.1.1 Extraction Optimization: Time Point Comparison 
Detector response measured as analyte peak area was collected for each 
benzodiazepine analyte included in this study after extraction with methanol using three 
agitation methods (rapid agitation (Tissuelyzer®), sonication, vortexing).  Detector response 
was measured over a total time period of 60 minutes with the response of each analyte 
measured after 5, 10, 15, 30, 45 and 60 minutes. Response was interpreted as the quantity of 
drug extracted at a particular time as the extraction solvent was collected for each extraction 
time and fresh solvent was added between each collection time. The mean response was 
compared between the three agitation methods at each concentration tested to evaluate the 
amount of drug extracted by each method. Figure 3.1 shows the difference in response at 
each concentration for each of the methods tested for lorazepam. The general trends observed 
in this figure were comparable to the other analytes measured. Rapid agitation tended to have 
the highest measured response for the 150 and 450 ng/mL trials, followed by sonication and 
then vortexing. The values at 15 ng/mL showed similar trends on a smaller scale. Rapid 
agitation demonstrated the highest response and sonication and vortexing tended to be very 
close in response across the agitation methods. Figures for other analytes and values used are 
found in Appendix A. The intra-assay precision, calculated by the coefficient of variation 
(CV%) of the measured triplicate values, was also compared between the three agitation 
methods. Figure 3.2 shows the difference in coefficients of variation for each of the 
benzodiazepines detected. The figure shows that data from extracted DBS spotted with blood 
at 15 ng/mL, is consistent with trends observed with DBS at 150 ng/mL. Sonication had the 
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lowest coefficient of variation over the majority of analytes, at values below the 20% 
threshold recommended by SWGTOX for reliability of a method. Vortexing and rapid 
agitation showed a greater variability of results with some values exceeding the 20% 
threshold. LRZ and NDZ exceeded 20% CV for rapid agitation, and DZP, 7CLZ, NDZ, and 
aHAM exceeded 20% for vortexing. At 150 ng/mL, sonication displayed the lowest 
coefficient of variation for all benzodiazepines except aHAM where vortexing instead had the 
lowest calculated value. Vortexing resulted in the highest calculated values for DZP, 7CLZ, 
LRZ, APZ, CLZ, NDZ, and TMZ while rapid agitation had the highest value for OXZ and 
aHAM. At the highest concentration, vortexing resulted in the highest values above 20% for 
all drugs. Rapid agitation showed the smallest values, all below 20%, at 450 ng/mL, except 
for aHAM. Sonication resulted in values all below 20% except for TMZ. Results for all 
analytes are presented in Appendix A. Sonication appeared to display the lowest coefficient 
of variation over the majority of analytes. The relative recovery of each analyte was 
calculated for each extraction time as the percent of response at each time to total response 
over the 60 minutes tested. Figure 3.3 illustrates relative recovery of lorazepam at each time 
point analyzed comparing the three agitation methods of interest. The trend of the data in 
Figure 3.3 is consistent with the trends observed with the other benzodiazepines measured as 
well as the internal standards used; these results can be found in Appendix A. The majority of 
extracted benzodiazepines were removed after the first 5 minutes with calculated relative 
responses between 81.1-92.6% for rapid agitation; 83.1-100% for sonication; and 80.8-100% 
for vortexing, across all concentrations. After 10 minutes the relative responses across all 
concentrations are 6.8-18.9% for rapid agitation, 5.4-16.9% for sonication and 5.0-19.1% for 
vortexing. The majority of each benzodiazepine was extracted completely by 15 minutes; 
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only DZP was extracted at the lowest concentration with a 1.4% relative recovery. Between 
150 and 450 ng/mL the relative recovery was 0-1.7% for rapid agitation, 0-1.2% for 
sonication and 0.4-1.0% for vortexing. Negligible amount of drug was extracted after that 
time point. 
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Figure 3.1: Measured response of lorazepam at each of the 3 concentrations tested (15, 150, 
450 ng/mL) and at each of the three different agitation methods (Tissuelyzer®, sonication, 
vortexing). Each measurement was performed in triplicate (n=3).  
 
 
 
0 
200 
400 
600 
800 
1000 
1200 
1400 
1600 
1800 
5 10 15 30 45 60 
M
ea
n 
Pe
ak
 A
re
a 
Time (min) 
Tissuelyzer 15ng/ml Tissuelyzer 150ng/ml Tissuelyzer 450ng/ml 
Sonication 15ng/ml Sonciation 150ng/ml Sonication 450ng/ml 
Vortexing 15ng/ml Vortexing 150ng/ml Vortexing 450ng/ml 
	  	   37	  
 
Figure 3.2: Coefficient of variation in percent of each analyte (DZP, 7CLZ, LRZ, OXZ, 
APZ, CLZ, NDZ, aHAM, TMZ) measured from DBS at 15 ng/mL after 5 minutes of 
extraction comparing each of the three agitation methods (Tissuelyzer®, sonication, 
vortexing). Each value was made from measurements made in triplicate (n=3). 
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Figure 3.3: The relative recovery to the total amount of analyte extracted after 60 minutes in 
percent of lorazepam measured at each time point after extraction from a DBS spotted with 
450 ng/mL using each of the three different agitation methods (Tissuelyzer®, sonication, 
vortexing) extracting from a DBS of 450 ng/mL. Each measurement was made in triplicate 
(n=3). 
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3.1.2 Extraction Optimization: Solvent Comparison 
 Four different solvents were assessed for optimization of extraction from DBS. 
Optimization of an extraction method includes selecting conditions producing high yield of 
the analytes, measured by calculating recovery. Acceptable precision was indicated by a CV 
of 20% or less. Maximization of precision is achieved by minimizing the coefficient of 
variation value. Optimization of matrix effects is also required for LC methods. SWGTOX 
standards require that matrix effects be within ±25%. The four solvents were; methanol, 
methanol:acetonitrile (1:1 v/v), methanol with 1 % formic acid, and methanol:acetonitrile 
(1:1 v/v) with 1 % formic acid. The response ratio of each benzodiazepine was measured and 
used to calculate the parameters compared. These values were calculated using response from 
DBS spiked pre-extraction, spiked post-extraction and neat standards. The recovery, 
precision, and matrix effects were compared for each of the nine drugs of interest for each 
solvent. Table 3.1 presents the matrix effects calculated for each drug at each concentration 
measured, 15, 150 and 450 ng/mL. Extraction solvents including formic acid presented ion 
suppression for more analytes and those without presented ion enhancement for all drugs 
except LRZ extracted with MeOH at 15 and 450 ng/mL. Most values for all extraction 
solvents considering the standard deviation (SD) exceeded the limit of ±20% presented by 
SWGTOX. MeOH as an extraction solvent resulted in calculated coefficients of variation < 
20% for all drugs at 15 and 150 ng/mL; the coefficient of variation was 30.6-40.7% for all 
drugs at 450 ng/mL. Using MeOH with 1% formic acid, the range of CV% was < 20% for all 
drugs at all concentrations except aHAM at 15 ng/mL with a CV% of 32.3%. All CV% 
values for both MeOH:ACN and MeOH:ACN with 1 % formic acid were < 20% for all 
concentrations. All average recovery values for all drugs, with the exception of 7CLZ, for all 
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extraction solvents assessed at all concentrations exceeded the lowest recovery calculated of 
aHAM of 118.5% after extraction using MeOH with 1 % formic acid. The metabolite 7CLZ 
had a range of average recovery of 45.3 - 64.8% with MeOH, 45.6 - 58.3% for MeOH and 1 
% formic acid, 75.5 - 83.6% with MeOH:ACN, and 59.6 - 70.9% with MeOH-ACN with 1 % 
formic acid. Specific values can be found in Appendix A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   41	  
Table 3.1: Calculated matrix effects values (±SD) of each of the nine analytes at each 
concentration (ng/mL) for each of the four different extraction solvents assessed; methanol 
(MeOH), methanol with 1% formic acid, 1:1 (v/v) methanol: acetonitrile (MeOH:ACN), and 
1:1 (v/v) methanol: acetonitrile with 1% formic acid. Each condition was repeated in 
triplicate (n=3) 
Extraction 
Solvent 
MeOH MeOH with 1% Formic 
Acid 
MeOH:ACN (1:1, v/v) MeOH:ACN (1:1, v/v) with 
1% Formic Acid 
Conc. 
(ng/mL) 
15 150 450 15  150  450 15 150 450 15 150 450 
DZP 31±12 39±8 19±1 -28±7 -28±5 -42±27 26±24 13±5 11±5 -16±5 -22±10 -29±8 
7CLZ 15±11 19±7 2±3 -27±6 -27±4 -41±8 34±12 16±5 16±3 -31±2 -31±9 -38±5 
LRZ -10±20 8±10 -7±2 -45±10 -53±5 -61±26 43±22 14±7 11±6 -22±12 -17±8 -28±5 
OXZ 59±18 85±15 59±5 -42±10 -28±5 -38±20 12±31 24±8 21±3 -21±2 -8±9 -16±5 
APZ 86±24 97±18 35±3 -1±11 -8±4 -39±15 42±20 29±6 30±10 -9±4 -18±14 -22±16 
CLZ 74±14 62±10 33±3 -37±3 -47±4 -58±30 28±28 15±5 14±5 -36±7 -39±7 -49±6 
NDZ 31±4 42±11 20±2 -47±4 -43±24 -56±33 27±24 16±6 12±4 -37±10 -37±9 -45±8 
aHAM 134±29 119±15 77±1 101±38 61±10 29±15 73±43 44±7 39±4 159±17 66±19 39±7 
TMZ 45±28 54±14 23±3 -31±16 -32±18 -47±26 62±13 12±4 12±5 -37±25 -29±8 -36±6 
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3.1.3 Internal Standard Application Comparison 
The addition of internal standard is an important requirement that allows for 
correction in extraction efficiency and intra-sample injection variability. Three different 
application conditions were measured: the addition of the internal standard to the spot with a 
dry time of 2 hours, no dry time after addition to the spot after it had been punched out, and 
adding the internal standard directly to the extraction solvent. Variability in precision was the 
parameter being measured. Figure 3.4 shows the calculated coefficient of variation for each 
of the 3 methods that were measured for each of the six internal standards that were used for 
this method: oxazepam-d5(OXZ-d5), 7-aminoclonazepam-d4(7CLZ-d4), nordiazepam-d5 
(NDZ-d5), alprazolam-d5(APZ-d5), α-hydroxyalprazolam-d5 (aHAM-d5), and diazepam-d5 
(DZP-d5). The coefficient of variation observed in adding internal standard to the extraction 
solvent was much lower than the other two methods; the CV% was < 20% for all standards. 
No dry time produced CV% values all below 20% with the exception of 7CLZ-d4. The CV% 
values with a 2-hour dry time were below 20% for 7CLZ-d4, NDZ-d5, and DZP-d5. Table 3.2 
shows results of student t-tests performed to measure the difference between each pair of 
conditions. A p-value of < 0.05 was considered to demonstrate a significant difference. No 
significant difference was found between the coefficients of variations comparing no dry time 
and 2 hour dry time methods. Significant differences were found between adding the internal 
standard to the extraction solvent and the two other application methods. 
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Figure 3.4: Calculated coefficient of variation in percent of each of the six deuterated 
internal standards used; oxazepam-d5 (OXZ-d5), 7-aminoclonazepam-d4 (7CLZ-d4), 
nordiazepam-d5 (NDZ-d5), alprazolam-d5 (APZ-d5), alpha-hydroxyalprazolam-d5 (aHAM-d5), 
and diazepam-d5 (DZP-d5). Each resulting from 20 µL of a 0.5µg/mL mixture added to each 
DBS extracted. Each measurement was made in triplicate (n=3) 
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Table 3.2: Calculated p-values for each internal standard analyzed by Student t-tests 
comparing each pair of parameters of internal standard application: i) addition of internal 
standard 2 hours dry time before extraction, ii) no dry time for internal standard before 
extraction, iii) adding the internal standard directly to the extraction solvent. Coefficient of 
variation was the point of comparison, calculated from response collected in triplicate (n=3) 
for each parameter. Significant differences are indicated.  
Application 
Conditions 
Compared 
p-value (ISTD) 
DZP-d5 OXZ-d5 NDZ-d5 7CLZ-d4 APZ-d5 aHAM-d5 
2h dry vs no dry 
 
0.371 0.427 0.385 0.853 0.345 0.369 
No dry vs extraction 
solvent 
 
0.004* 0.004* 0.004* 0.006* 0.00005* 0.000096* 
2h dry vs extraction 
solvent 
0.004* 0.006* 0.005* 0.000043* 0.00047* 0.00025* 
* significant statistical difference calculated (p-value<0.05) 
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3.1.4 Solvent Clean-up: Addition of Protein Filtration Step 
Addition of a solvent clean-up step during sample preparation was assessed to try to 
reduce matrix effects within the ±25% threshold outlined in SWGTOX for method reliability 
for a quantitative method. The addition of a protein filtration step using a 96-well Clean 
Screen® FASt plate to filter out macromolecules >1µm in size was compared to a sample 
preparation without. Figure 3.5 shows the comparison of matrix effects between sample 
preparation with and without protein filtration. The figure shows the matrix effects at 15 
ng/mL for all drugs measured; the same trend is observed across all concentrations that were 
assessed. Across all drugs there was a decrease in the measured matrix effects when 
including protein filtration by Clean Screen® FASt plate. The recovery of each analyte was 
also measured and compared between sample preparation with and without the protein 
filtration step (Figure 3.6). Again, the same trend is observed across all concentrations; 
Figure 3.6 presents the results from 15 ng/mL DBS. The recovery calculated was found to be 
lower for all analytes when protein filtration was included. 
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Figure 3.5:  Calculated matrix effects of each of the benzodiazepines analyzed (±SD) 
comparing the addition of protein filtration of the extraction solvent using a 96-well Clean 
Screen® FASt plate to a procedure without. These data are calculated from DBS at 15 
ng/mL, each measurement was made in triplicate (n=3). 
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Figure 3.6: Calculated recovery (±SD) of each of the analytes comparing the use of the 96 
well Clean Screen® FASt plate for protein filtration of the extraction solvent to a procedure 
excluding this step. These data are calculated from DBS at 15 ng/mL, results were collected 
in triplicate (n=3). 
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3.1.5 Optimization of Protein Filtration: Comparison of Solvent Systems 
Matrix effects for the inclusion of protein filtration still demonstrated high matrix 
effects outside the ±25% threshold that was established by SWGTOX guidelines for reliable 
quantitative methods and the recovery also had an observable decrease with the inclusion of 
this step. Four different solvent systems were then tested to decrease matrix effects and 
increase recovery: extraction in 1:1 methanol:acetonitrile; extraction in 1:1 methanol 
acetonitrile with 1% formic acid; extraction in 1:1 methanol:acetonitrile with addition of 1 
mL of acetonitrile to the extraction solvent before filtration; and extraction in 1:1 
methanol:acetonitrile with addition of 1 mL of acetonitrile with 1% formic acid to the 
extraction solvent before filtration. Precision, recovery, and matrix effects were compared for 
all analytes in order to optimize the protein filtration step. Precision, measured using 
coefficient of variation (CV%), met the < 20% SWGTOX criterion for all drugs with all 
solvent systems assessed, with the exception of aHAM using MeOH:ACN with the additional 
1mL of ACN, with a CV% of 22.0%. Figure 3.7 shows the calculated matrix effects extracted 
from a 15 ng/mL DBS for all benzodiazepines in this study. The graph shows both 
suppression and enhancement of the analytes. Similar trends were observed at 150 and 450 
ng/mL (presented in Appendix A). Matrix effects when extracted in MeOH:ACN were 
consistently outside the ±25% range given by SWGTOX; all values demonstrated ion 
suppression above 25%. Using MeOH:ACN with 1% formic acid (FA) as the extraction 
solvent, 7CLZ and APZ exceeded the SWGTOX threshold at both 15 ng/mL and 150 ng/mL, 
7CLZ displayed ion enhancement and APZ displayed ion suppression. At 450 ng/mL APZ 
and CLZ both demonstrated ion suppression beyond 25%. This solvent system predominantly 
resulted in ion suppression, more evident at the higher concentrations than at 15 ng/mL. 
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Using the resulting matrix effects, the solvent systems were narrowed to a choice between 
two. Average recovery was compared between extraction in 1:1 MeOH:ACN with addition of 
1 mL of ACN before filtration; and extraction in 1:1 MeOH:ACN with addition of 1 mL of 
ACN with 1% FA. Figure 3.8 compares the recovery between the two solvent systems from 
15 ng/mL DBS; a similar trend was observed at the other three concentrations (presented in 
Appendix A). At 15 and 150 ng/mL the average recovery from MeOH:ACN with 1 mL ACN 
added post-extraction before filtration appeared to be higher for most analytes however the 
standard deviation for most drugs overlaped, suggesting the two were not significantly 
different in recovery. However at 450 ng/mL there was no overlap of average recovery and 
respective standard deviations between the two conditions tested for 7CLZ, LRZ, OXZ, APZ, 
CLZ, NDZ, and TMZ when MeOH:ACN with 1 mL ACN was added post-extraction before 
filtration for all compounds with a higher recovery value (presented in Appendix A).  
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Figure 3.7: Calculated matrix effects (±SD) of each benzodiazpine from each solvent system 
measured to optimize protein filtration with a Clean Screen® FASt plate: 1:1 (v/v) 
MeOH:ACN (methanol: acetonitrile); MeOH:ACN with 1% formic acid (FA); 1:1 (v/v) 
MeOH:ACN with 1 mL ACN added post-extraction before filtration; 1:1 (v/v) MeOH:ACN 
with 1 mL ACN with 1% FA added post-extraction before filtration. These data are 
calculated from 15 ng/mL DBS measured in triplicate (n=3). 
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Figure 3.8: Calculated recovery (±SD) of each benzodiazepine extracted with MeOH:ACN 
with the addition of 1 mL of ACN to the extraction solvent before filtration compared to 
extraction with MeOH:ACN with the addition of 1 mL of ACN with 1% of formic acid (FA) 
to optimize the solvent system. These data are calculated from DBS at 15 ng/mL collected in 
triplicate (n=3). 
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3.1.6 Optimization of Reconstitution Solvent 
Further optimization to increase recovery was continued to compare the reconstitution 
in mobile phase A (MPA) of 5 mM ammonium formate in water with 1% formic acid to 
reconstitution in 1:1 (v/v) acetonitrile:water (ACN:H2O). Figure 3.9 shows the comparison of 
the calculated average recovery of each benzodiazepine between the two reconstitution 
conditions. The same trend was observed at both 150 and 450 ng/mL. After evaporating the 
extraction solvent to dryness, reconstituting the analytes in the ACN:H2O demonstrated a 
higher percentage of recovery than with MPA.  The only analyte that showed a decrease in 
recovery was 7CLZ, and this was observed at each of the three concentrations of extracted 
DBS analyzed. 
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Figure 3.9: Recovery of each benzodiazepine comparing reconstitution after evaporation 
dryness in mobile phase A (MPA) and reconstitution in 1:1 (v/v) acetonitrile: water 
(ACN:H2O) to optimize the recovery of the final step. These data show results from DBS at 
150 ng/mL collected in triplicate (n=3). 
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3.1.7 Analyte Stability in DBS 
The stability of each analyte within the Whatman 903 Protein Saver cards was 
evaluated over 28 days with measurements of response being made at 1, 2, 7, 14, and 28 
days. Measurement was made to quantify degradation that may occur over time and compare 
two storage temperatures, ambient temperature and refrigeration at 4°C. The response ratio 
was measured and compared over time at three concentrations (15, 150, and 450 ng/mL). 
Any change of response ±20% from the initial response on day 1, was considered a 
significant change, indicating a notable change in the concentration of the analyte. Figure 
3.10 illustrates the relative response over time to response on day 1 of temazepam at each 
time point measured, calculated compared to the initial day 1 response and represented in 
comparison to day 1 as 100% of the expected response at ambient temperature. Figure 3.11 
illustrates the relative response to the initial response measured on day 1 of temazepam while 
refrigerated. Under both conditions a decrease in response at 28 days at all 3 concentrations 
was observed that dropped below a 20% change from the initial measured response ratio. 
This trend was only observed for temazepam. Figure 3.12 shows the change over the 
observed time period of the relative response to response measured on day 1 ± standard 
deviation (SD) of alprazolam under ambient conditions and Figure 3.13 shows the same 
parameters measured from DBS stored at 4°C. Day 1 represented 100% response and all 
measured responses being measured relative to that value. There was an observed increase in 
the relative response over time of 15 ng/mL DBS both at ambient temperature and 
refrigeration. Under both conditions the relative response change extended above a 20% 
change in response indicating a significant change. This was a common trend observed. 
Analytes that demonstrated this trend after 14 days are indicated in Table 3.3 while those 
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showing this trend after 28 days are indicated in Table 3.4. The tables indicate the percent 
change in response above or below the measured response relative to that on day 1. The 
metabolite 7CLZ showed a significant increase over 20% at 14 days at room temperature not 
seen when stored by refrigeration. DZP, APZ, and aHAM demonstrated significant increases 
in response change at 15 ng/mL at 28 days under both conditions. LRZ showed a significant 
increase at 28 days at room temperature and no significant change under refrigeration, while 
CLZ demonstrated a significant increase at 15 ng/mL and 150 ng/mL under both conditions. 
Both tables give the value of relative response change ± SD for each compound. Values from 
2 and 7 days were not presented as all changes in response were < 20% for all compounds, 
therefore no significant changes in analyte response were seen at all concentrations up to 7 
days.  
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Figure 3.10: Relative response change in percent at 3 concentrations (15, 150, 450 ng/mL) of 
temazepam over time after storage at ambient temperature after 2, 7, 14, and 28 days 
measured relative to the response on day 1. Measurements were collected in triplicate (n=3). 
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Figure 3.11: Relative response change in percent at 3 concentrations (15, 150, 450 ng/mL) of 
temazepam over time after storage in a refrigerator at 4°C after 2, 7, 14, and 28 days 
measured relative to the response on day 1. Measurements were collected in triplicate (n=3). 
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Figure 3.12: Relative response change in percent at 3 concentrations (15, 150, 450 ng/mL) of 
alprazolam over time after storage at ambient temperature after 2, 7, 14, and 28 days 
measured relative to the response on day 1. Measurements were collected in triplicate (n=3). 
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Figure 3.13: Relative response change in percent at 3 concentrations (15, 150, 450 ng/mL) of 
alprazolam over time after storage in a refrigerator at 4°C after 2, 7, 14, and 28 days 
measured relative to the response on day 1. Measurements were collected in triplicate (n=3). 
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Table 3.3: Relative response change (±SD) of each benzodiazepine measured relative to the 
measurement of response on day 1 after 14 days in both conditions assessed; ambient 
temperature and refrigeration at 4 ºC. Incidences of significant change in relative response are 
indicated. Measurements were collected in triplicate (n=3). 
 Relative Response Change (%) after 14 days 
 Ambient Temperature Refrigeration (4ºC ) 
Conc. 
(ng/mL) 
15 150 450 15 150 450 
DZP 11.9±2.4 6.4±5.1 -3.5±3.1 7.5±3.0 2.4±2.7 0.9±7.4 
7CLZ 31.6±5.4** 13.1±10.8** 9.0±3.8 -2.7±6.8 -8.5±1.4 -3.6±4.4 
LRZ 3.4±5.1 -1.7±4.8 -9.9±3.3 -5.1±3.3 -4.6±2.8 -5.6±5.6 
OXZ 3.0±2.1 -2.8±5.3 -8.5±4.4 -8.2±5.1 -6.7±1.6 -6.3±7.0 
APZ 8.0±1.1 3.1±5.0 -6.1±3.6 2.6±2.1 -2.4±2.8 -3.4±7.4 
CLZ 12.6±0.1 13.7±4.4 -0.8±3.6 6.3±4.0 8.8±4.1 2.4±8.5 
NDZ 6.8±9.7 -0.4±4.8 -5.8±4.3 -7.9±2.6 -7.5±4.4 -3.6±7.3 
aHAM 13.2±3.1 4.8±5.1 -10.1±3.0 5.1±4.2 -1.7±1.7 -8.3±7.4 
TMZ 12.2±2.3 9.5±6.8 0.05±5.9 9.0±3.3 4.5±1.7 3.1±8.6 
** Increase in relative response (%) exceeds ±20% threshold indicative of significant change 
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Table 3.4: Relative response change (±SD) of each benzodiazepine measured relative to the 
measurement of response on day 1 after 28 days in both conditions assessed; ambient 
temperature and refrigeration at 4 ºC. Incidences of significant change in relative response are 
indicated. Measurements were collected in triplicate (n=3). 
 Relative Response Change (%) after 28 days 
 Ambient Temperature Refrigeration (4ºC ) 
Conc. 
(ng/mL) 
15 150 450 15 150 450 
DZP 30.3±3.0** -10.8±3.7 6.2±3.6 23.8±6.7** 13.2±6.3 7.6±2.4 
7CLZ -3.2±8.9 -2.3±5.4 -11.6±2.7 3.3±8.5 -6.5±9.2 -13.0±3.3 
LRZ 22.9±9.0** 4.6±5.1 -3.4±2.3 7.8±10.1 3.2±5.6 -1.7±1.8 
OXZ 5.2±4.2 -5.0±5.0 -10.8±2.3 8.8±3.2 -0.4±4.9 -7.4±2.3 
APZ 27.2±4.1** 4.1±2.9 -1.8±2.6 20.4±9.8** 4.61±7.8 -0.7±2.0 
CLZ 41.7±5.6** 20.4±5.5** 8.1±2.8 23.0±3.6** 23.2±8.9** 12.2±2.3 
NDZ 14.4±4.1 2.6±5.6 -6.7±3.3 8.9±7.5 0.2±5.3 -6.2±2.7 
aHAM 27.9±4.2** 8.1±4.3 -3.9±4.3 16.6±6.3** 8.5±7.1 -7.4±1.5 
TMZ -25.0±2.4* -33.9±2.5* -39.5±1.4* -26.8±0.9* -32.9±4.8* -37.3±1.8* 
* Decrease in relative response (%) exceeds ±20% threshold indicative of significant change 
** Increase in relative response (%) exceeds ±20% threshold indicative of significant change 
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3.1.8 Autosampler Stability 
Stability of each of the analytes at three concentrations (15, 150, and 450 ng/mL) was 
assessed not only within the card matrix but also within the autosampler of the instrument. 
Each analyte was assessed over a 36 hour period to measure stability within the reconstitution 
solvent of ACN:H2O at the constant 10°C to assess the length of time samples can wait to be 
sampled. The response ratio was calculated at 0, 12, 24, and 36 hours after reconstitution, and 
the relative response was calculated in relation to the initial response at 0 hours. Any change 
±20% from the initial response from 0 hours was considered a significant change in response 
ratio indicating a notable change in the stability of the compound. Table 3.5 shows the 
relative response change ±SD calculated at 12, 24, and 36 hours at all concentrations of DBS 
extracts assessed. The change in relative response that exceeds ± 20% is indicated in Table 
3.5. TMZ demonstrated an increase in response at the high concentration at 24 and all 
concentrations at 36 hours. CLZ also showed an increase with a SD extending above a 20% 
change after 12 and 24 hours. LRZ demonstrated a decrease with a SD extending below a 
20% change in response at 24 hours. OXZ showed a response above 20% at 24 hours. 7CLZ 
showed a decrease in response at 24 hours. 
 
 
 
 
 
 
 
	  	   63	  
Table 3.5: Relative response change (±SD) of each benzodiazepine measured relative to the 
measurement of initial response at 0 hours after 12, 24, and 36 hours in the autosampler held 
at a constant 10°C. Incidences of significant change in relative response are indicated. 
Measurements were collected in triplicate (n=3). 
 Relative Response Change (%) 
 12 hours 24 hours 36 hours 
Conc. 
ng/mL 
15 150 450 15 150 450 15 150 450 
DZP 4.2±3.7 2.3±3.8 -0.9±5.4 -6.3±4.2 -1.5±9.7 -1.0±6.3 -5.4±4.6 0.3±4.3 -2.7±2.8 
7CLZ 3.6±7.6 -6.1±4.5 -8.0±6.1 -18.9±4.5* -5.5±4.7 -2.5±6.6 3.4±7.1 -0.2±5.0 -4.3±5.2 
LRZ -5.8±3.3 -0.2±6.9 4.4±5.3 -13.4±6.9* -3.8±6.0 3.7±4.4 -4.9±6.2 -2.2±2.7 1.0±2.0 
OXZ 14.3±2.8 1.4±3.3 1.2±4.9 20.2±7.7* 1.2±3.8 2.8±4.8 9.2±10.6 -1.6±3.2 2.1±3.6 
APZ 6.1±4.7 1.1±8.8 4.4±3.9 -3.6±1.4 2.9±4.0 1.9±3.1 -6.1±1.0 -1.4±6.0 4.6±8.2 
CLZ 10.9±10.6* -3.6±7.5 1.2±4.9 16.5±4.4* -8.1±4.0 1.7±1.7 3.6±8.2 -10.7±5.2 -3.2±4.2 
NDZ -1.1±3.1 -9.0±5.9 0.5±5.3 3.6±6.2 -5.5±3.5 0.8±3.3 2.1±3.4 -2.5±3.8 3.2±4.4 
aHAM -1.0±6.6 -0.1±3.6 3.1±2.7 11.2±5.5 -1.5±6.5 2.3±5.0 3.0±6.2 -2.6±4.0 1.2±4.7 
TMZ 0.4±3.5 3.4±10.6 0.4±4.1 4.7±5.8 16.0±3.6 18.0±6.5* 9.7±12.0* 16.0±4.6* 18.1±5.3* 
* Change in relative response (%) exceeds ±20% threshold indicative of significant change 
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3.1.9 Effect of Hematocrit Variation 
The effect of hematocrit on the measured response ratio was assessed over a reported 
range of variability in humans. The response ratio was calculated for each analyte of interest 
at five different hematocrit levels: 20, 35, 45, 55, and 70%. Figure 3.14 shows the response 
ratio ±SD of each benzodiazepine compared at each hematocrit level tested. A Kruskal-
Wallis non-parametric test was performed for each drug to test if there was a significant 
difference between the response ratios of each drug measured from each hematocrit sample. 
Table 3.6 gives the calculated p-value for each drug and each concentration. A p-value that is 
< 0.05 is considered to be statistically significant. All drugs except LRZ and NDZ were found 
to have no significant difference across all hematocrit assessed at all benzodiazepine 
concentrations. LRZ at a concentration of 15 ng/mL and NDZ at a concentration of 150 
ng/mL each had statistically significant differences between hematocrit levels, with the other 
concentrations showing no significant differences. A post-hoc Nemenyi style test was 
performed to identify which hematocrit values had significant statistical differences. For LRZ 
a significant difference was found between 20% and all other hematocrit values and between 
70% and all other hematocrit values. NDZ was calculated to have statistically significant 
differences between 20% and all other hematocrit values and 55% from all other hematocrit 
values. 
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Figure 3.14: Measured response ratio (±SD) of each benzodiazepine comparing the response 
at each of the five hematocrit percentages; 20, 35, 45, 55, and 70%. These data present the 
results from DBS at 15 ng/mL. Measurements were collected in triplicate (n=3) at each 
concentration and hematocrit.  
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Table 3.6: Calculated p-values from Kruskal-Wallis non-parametric test performed to assess 
significant difference in response ratio between hematocrit levels measured for each drug. 
Results for drug concentrations of 15, 150, and 450 ng/mL presented. Each treatment was 
measured in triplicate (n=3). 
Benzodiazepine 
Concentration 
(ng/mL) 
p-value of comparison between 5 hematocrit levels 
DZP 7CLZ LRZ OXZ APZ CLZ NDZ aHAM TMZ 
15  0.054 0.099 0.045* 0.384 0.569 0.153 0.223 0.075 0.274 
150  0.545 0.106 0.197 0.129 0.160 0.479 0.048* 0.151 0.265 
450 0.082 0.098 0.099 0.095 0.067 0.099 0.067 0.151 0.061 
* p-value<0.05 indicating a statistically significant difference between groups 
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3.2 Method Validation 
To validate this method for quantitative use, calibration curves for each analyte were 
produced on five separate days. Response ratio for seven data points, 7.8, 15.6, 31.25, 62.5, 
125, 250, and 500 ng/mL was measured. Figure 3.13 is a calibration curve completed for 
diazepam. Each curve was fit with a quadratic line of best fit, and the equation of the line and 
the R2 were given for each graph. A calibration curve was produced for each of the drugs on 
each of the five days curves were analyzed. The R2 value for all curves on all days was 1.00 
with the exception of 7CLZ, LRZ, and OXZ for curve 1, producing R2 of 0.998, 0.999, and 
0.999 respectively. Precision was assessed as intra-assay with replicate analysis (n=3) 
measured using coefficient of variation. All drugs at all concentrations met the SWGTOX 
guidelines of a CV% of less than 20% except TMZ from the first curve at 7.8 ng/mL at 
22.6%. Across all curves the range of CV% was 0.8 – 18.1% for DZP; 0.9 - 19.2% for 7CLZ; 
0.8 - 19.9% for LRZ; 1.7 - 18.8% for OXZ; 1.4 - 10.7% for APZ; 0.2 - 13.6% for CLZ; 0.8 - 
11.5% for NDZ; 0.3 - 15.6% for aHAM; and 0.9 - 22.6% for TMZ. CV% for all blind 
accuracy samples at low and high concentrations had CV% < 20%. The equation of the line 
was used to calculate two blind accuracy samples that were analyzed at the same time as the 
curve, one low and one high concentration. This was completed for curves 2-5. This 
calculated concentration was then compared to the actual value of concentration to measure 
bias. Bias is the measurement of accuracy. SWGTOX sets a bias threshold of ≤ 20% 
difference between the calculated and actual value. The bias values for all high 
concentrations met this threshold. Across all drugs a range of 2.2-18.5% was calculated for 
the blind high concentration samples from all four curves where accuracy samples were 
included. The calculated values for the low concentrations are given in Table 3.7. Values 
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where the bias exceeded the 20% SWGTOX threshold are indicated in Table 3.7. DZP, 
7CLZ, OXZ, CLZ, and TMZ all had one curve where the bias exceeded 20% while NDZ and 
aHAM had two curves with accuracy samples that exceeded 20%. All bias values can be 
found in Appendix A. 
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Figure 3.15: Calibration curve of diazepam measuring the relationship between response 
ratio and concentration across a range of 7.8 ng/mL – 500 ng/mL. (n=3) Line fit with a 
quadratic regression line. The equation of the line and the R2 value are shown. 
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Table 3.7: Calculated bias of measured concentration to actual value of blind low 
concentration analyte sample for each benzodiazepine measuring the accuracy of the method 
for curves 2-5. Calculated from measurements made in triplicate (n=3). Values exceeding 
SWGTOX threshold indicated. 
Curve Calculated Bias (%) 
DZP 7CLZ LRZ OXZ APZ CLZ NDZ aHAM TMZ 
2 14.80 16.58 12.27 16.91 11.75 16.30 16.56 21.66* 12.49 
3 22.23* 11.02 10.01 21.80* 19.22 21.37* 23.14* 25.61* 14.80 
4 15.42 25.43* 10.39 13.61 10.99 11.67 23.72* 18.32 20.16* 
5 1.65 11.29 12.20 9.35 9.57 8.15 8.34 12.01 9.11 
* Bias exceeds 20% threshold established in SWGTOX guidelines  
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CHAPTER 4: DISCUSSION 
This research was conducted in order to develop a screening method for the detection 
of nine benzodiazepine and benzodiazepine metabolites in blood after collection using dried 
blood spots  (DBS) with analysis by ultra-performance liquid chromatography-quadrupole 
time of flight-mass spectroscopy (UPLC-QTOF-MS). Guidelines and thresholds supported 
by SWGTOX for reliable quantitative methods were followed to determine if this method 
could be classified as quantitative or semi-quantitative. This would allow quantification of 
each drug contained within the DBS either with a corresponding concentration or determining 
the concentration to be one of impairment or not. The method was developed completing a 
number of experiments in order to optimize the steps and minimize time and effort required 
for extraction. The stability of the analyte was assessed within the card matrix under different 
storage conditions as well as within the reconstitution solvent held in the autosampler. The 
potential effect of hematocrit on the interpretation of the concentration was also measured. 
After these steps the method was validated by producing calibration curves to measure the 
bias and therefore accuracy of the method within and between days as well as the precision. 
Current legislation that controls the collection of biological samples from road side 
detentions in suspected drug impaired driving cases produces long delays between the time of 
detention and the time of sampling that can influence the interpretation of measured 
concentrations in blood. Current collection of blood, the sample of choice for drug impaired 
driving, is an invasive process that requires certified personnel to draw the sample, and more 
complicated storage considerations. DBS is proposed as a way to simplify collection and 
storage as well as extraction procedures. 
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4.1 Solvent-Spot Agitation Method 
 In order to determine the most effective method of solvent-spot agitation and the time 
that would optimize the recovery, precision, extraction time, and throughput of each 
benzodiazepine, three different agitation methods were compared (rapid agitation 
(Tissuelyzer®), sonication, and vortexing) over 60 minutes in triplicate. Extraction was 
achieved with methanol. The response of each of the analytes was compared between three 
different agitation methods at each time point where the extraction solvent was collected. 
This was compared at three different concentrations, a high (450 ng/mL), middle (150 
ng/mL) and low (15 ng/mL) value that covered a comprehensive range of impairing 
concentrations of each benzodiazepine. Lorazepam was shown as an example of the 
comparison of the response, interpreted as the quantity of drug being extracted by a given 
method at a given time, between each of the extraction methods at three different 
concentrations (Figure 3.1). This response showed a similar trend in all drugs measured. 
Rapid agitation consistently demonstrated the highest response in peak area for each drug 
with the exception of OXZ, where sonication had the largest response. This was seen at the 
high and medium concentrations. At the low concentration the peak areas tended to be close 
in value, with rapid agitation and vortexing responses generally slightly above sonication. 
Based on response alone, rapid agitation showed the largest response and therefore most 
extracted drug. However the method itself was very variable in visible destruction of the spot, 
with some spots being pulverized by the motion of the Tissuelyzer® and others not showing 
any damage. The variability observed was suspected to be caused in part by non-uniform 
motion across plate over which the samples were distributed. Pulp present in the sample was 
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also a concern for interfering with later steps, and added the requirement of a second 
centrifugation step.  
The precision of the measurements was the next parameter assessed to determine the 
best agitation method for DBS to extract the analytes of interest. The coefficient of variation 
was used to measure the precision of the calculated response ratios. Sonication appeared to 
have the best precision, with all CV% for the low and medium concentrations being below 
the 20% threshold specified by SWGTOX, and all CV% at 450 ng/mL but CLZ and TMZ 
were < 20%, as observed in Figure 3.2 with data after collection at 5 minutes. Beyond 5 
minutes measurements tended to show more variation over all methods analyzed. The CV% 
for vortexing and sonication is variable at the low concentrations but values for vortexing are 
generally higher than those of sonication. All methods showed precision below 20% for all 
drugs at 150 ng/mL except rapid agitation that exceeded a CV% of 20% for aHAM. All CV% 
values for vortexing at the high concentration had precision that exceeded 20% deviation 
from the value whereas rapid agitation and sonication were all below a CV% of 20%, except 
for TMZ. Precision consistently was the best using sonication considering all concentrations. 
Sonication was the final choice made for the solvent-spot agitation method based on a high 
level of response measured at 150 and 450 ng/mL, and a comparable response to the other 
two methods at 15 ng/mL, with the most consistent precision below the SWGTOX cutoff, 
and no visible destruction of the spot. Relative recovery over time compared to the total 
amount of analyte recovered after 60 minutes of collection was analyzed. The same trend 
observed in Figure 3.3 was observed for all drugs. For all agitation methods the highest 
recovery occured after 5 minutes; 80.8 -100% of each drug in the mix was extracted after the 
first 5 minutes across all three methods and concentrations. After 10 minutes, 5.0 - 19.1% of 
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analyte was extracted depending on the drug and for most analytes (except aHAM) there was 
still a measured response at 15 minutes at the mid and high concentrations. This suggested 
that an extraction time of 15 minutes would extract the maximum amount of each analyte 
from DBS at concentrations relevant to impairment. Recovery of 99% of the total quantity 
extracted of each analyte occurred in the first 15 minutes at all three concentrations.  
Maximizing recovery is important in the case of dry blood spots when starting with such 
small volumes of sample. Preliminary testing of extraction solvent had already been 
performed (results not included). The highest response was seen using methanol, suggesting 
the highest recovery of analyte; however, further testing was required to optimize the solvent 
used considering matrix effects. These experiments included solvents demonstrating less 
efficient extraction time therefore to account for a potentially longer extraction with the 
optimized solvent, the extraction time was extended to 30 minutes. 
 Important limits to this experiment to be considered in choice of agitation methods 
are that the application method of internal standard had still not been optimized and higher 
variability was observed in internal standard values when this method was used for 
application than the final method determined. This variability in internal standard values 
could have misrepresented the coefficient of variation values calculated for each agitation 
method. It was also the response that was compared between methods for the first 
comparison, not the response ratio, therefore variation in response of the detector and 
extraction efficiency were not accounted for. However, the variability in the internal standard 
measurements, if response ratio was used, may have also misrepresented the solvent-spot 
agitation method with the highest yield, as variability in internal standard could have 
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distorted the average response ratio that would have been used for comparison. The final 
choice was extraction by sonication for 30 minutes. 
 
4.2 Extraction Solvent 
Matrix effects, recovery, and precision were all assessed in order to optimize the 
extraction solvent to use with the chosen solvent-spot agitation method. Four solvents - 
methanol; 1:1 v/v methanol:acetonitrile; 1% formic acid in methanol; and 1% formic acid in 
1:1 v/v methanol:acetonitrile- at 3 concentrations- 15, 150, and 450 ng/mL- were compared 
in triplicate. Pre- and post-extraction spiked samples as well as neat standards were measured 
in order to calculate matrix effects and recovery. Matrix effects are an important 
consideration in methods that utilize liquid chromatography; ion suppression or enhancement 
must be restricted to a 25% change in response for quantitative methods by SWGTOX 
guidelines calculated from the neat standard with no matrix. Consideration must be given to 
matrix effects and recovery in the choice of extraction solvent due to the small quantity of 
analyte present, as only 20 µL of blood was used to produce each DBS. In this case any ion 
suppression of the response was to be avoided if possible. The majority of the matrix effects 
calculated for solvents including formic acid exceeded the 25% threshold given by SWGTOX 
for the appropriate amount of matrix effects for a quantitative method. The majority of the 
values were negative indicating ion suppression (Table 3.1). Therefore, MeOH with 1% 
formic acid and 1:1 (v/v) MeOH:ACN with 1% formic were no longer considered. 
Comparisons between the solvents MeOH and MeOH:ACN, at low drug concentrations 
showed no differences in matrix effects between solvents as there was an overlap in the error 
bars representing the standard deviation of the average matrix effect for each compound. This 
	  	   76	  
suggested the variability in measurements overlapped for the two solvents although the 
average matrix effect value for MeOH:ACN was lower for more benzodiazepines. However 
as the drug concentration increased, differences in matrix effect between solvents was noted 
for LRZ, OXZ, CLZ, aHAM and TMZ. Matrix effects calculated for MeOH:ACN ± SD were 
found to be lower than those of MeOH. This supported MeOH:ACN as the extraction 
solvent. 
Calculated precision values at all concentrations extracted using MeOH:ACN were < 
20%, within the acceptable limits of variation outlined by SWGTOX. MeOH had acceptable 
precision CV% at 15 ng/ mL and 150 ng/mL but all precision values at the high concentration 
exceeded the 20% threshold. All average recovery values were significantly above 100%, 
most above 120%. Even in cases where the matrix effects suggested ion suppression, the 
recovery values were still well above 100%. This suggested a matrix-drug interaction beyond 
the matrix effects that enhanced the response well above that detected in a neat standard at 
the expected final concentration. It may have been the result of the method followed to 
produce the post-spiked sample, causing an unexpected interaction with glassware or perhaps 
a loss during evaporation, reducing the amount of analyte measured. A protein filtration step 
was considered to further reduce the observed matrix effects and elevated recovery. Based on 
this experiment, 1:1 (v/v) MeOH:ACN  was chosen as the extraction solvent to minimize 
matrix effects measured, and increase precision of the measured values. A minimal volume of 
1 mL was chosen to ensure the spot was completed submerged in solvent. 
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4.3 Internal Standard Application 
Variability had been observed in the internal standard response that did not mirror the 
variability that was observed in response from the analytes extracted from the spot. Therefore 
different methods in applying internal standards were compared; addition of the internal 
standard to the spot with a dry time of 2 hours, no dry time after addition to the spot after it 
had been punched out, and adding the internal standard directly to the extraction solvent. The 
variability was observed in the coefficient of variation; a consistent volume (20 µL) was 
spotted to correct for differences in extraction efficiency and detector response that could 
occur due to subtle changes in conditions between samples. It was suspected that the initial 
way the internal standard was added, that is, addition to the spot before being punched out 
and with a 2 hour dry time, was causing variability as the blood spot already occupied much 
of the matrix of the filter paper. Therefore internal standard solvent diffused beyond the edge 
of the filter paper punched out for sampling, causing an uneven distribution of each internal 
standard, increasing the variation and causing misrepresentation of the variability of the 
response of each analyte. The CV% for each of the three methods was compared in Figure 
3.4. Values derived from adding the internal standard directly to the extraction solvent had a 
much lower CV% indicating a more precise measurement. Overall, addition of internal 
standard to the spot before punching out and leaving to dry for 2 hours had the lowest amount 
of precision, suggested by the large CV%.  Student t-tests were performed to assess if there 
was a significant difference between each of the three methods (Table 3.2). There was no 
significant difference between a 2-hour dry time adding to the card before spot removal and 
no dry time after spot removal. The CV% of adding directly to the extraction solvent was 
significantly different from the two other methods. Although adding the internal standard 
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directly to the extraction solvent before extraction did show the highest precision, it would no 
longer be able to be used to assess the extraction efficiency of the drugs from the spot as it is 
not being added directly to the spot on the card matrix, rather, directly to the extraction 
solvent, which negates this function of the internal standard. Although the internal standard is 
also not within the blood when added directly to the card, it is still being allowed to integrate 
within the matrix, and will be extracted to some extent along with the drugs of interest. This 
is also the approach that would need to be taken in casework, as the blood spotted from an 
individual would not include internal standard within the matrix. Therefore the final decision 
to increase the precision while still maintaining the functionality of the internal standard was 
to add internal standard to the spot after it had been removed.  
 
4.4 Extract Clean-up by Protein Filtration 
Optimization of the extraction solvent did not reduce the matrix effects within the 
SWGTOX standards of ±25% of the response of the neat standard absent of matrix of the 
expected concentration. Therefore the inclusion of a protein filtration step using a Clean 
Screen® FASt plate was included. The plate removes macromolecules that are >1µm in order 
to remove potential matrix components contributing to the observed matrix effects (e.g. 
phospholipids). Sample preparation with and without a protein filtration step were compared 
at three concentrations (15 ng/mL, 150 ng/mL, 450 ng/mL). There was a clear reduction in 
the calculated matrix effects (Figure 3.5) on all analytes for all compounds of interest, and 
this was observed at all concentrations. There was no overlap in standard deviation 
suggesting significant difference between matrix effects after protein filtration and matrix 
effects without filtration. However the matrix effect values all still appeared to be beyond the 
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±25% required by SWGTOX for quantitative methods. Recovery was also measured after the 
addition of the step. A clear drop in recovery can be seen for all analytes, in Figure 3.6 at all 
concentrations. This is expected as the addition of an extra filtration step produces 
opportunity where some analyte may be lost when associated with particles filtered out and 
interaction with additional materials may also cause a decrease in yield. In an effort to reduce 
the measured matrix effects and increase the recovery four different solvent systems were 
compared for protein filtration extraction - 1:1 methanol:acetonitrile; extraction in 1:1 
methanol acetonitrile with 1% formic acid; extraction in 1:1 methanol:acetonitrile with 
addition of 1 mL of acetonitrile to the extraction solvent before filtration; and extraction in 
1:1 methanol:acetonitrile with addition of 1 mL of acetonitrile with 1% formic acid to the 
extraction solvent before filtration. Similar to when the extraction solvent was chosen, 
avoidance of ion suppression was desired, in order to maximize response, as the quantity of 
analyte in each sample is reduced due to the small sampling volume. This eliminated 
MeOH:ACN with 1% formic acid; as extraction with this solvent showed a trend of increased 
ion suppression, indicated by negative matrix effect values, as the concentration increased. 
Suppression observed at 450 ng/mL extended beyond the -25% threshold of SWGTOX 
guidelines for multiple drugs, including LRZ, OXZ, and aHAM that had already 
demonstrated a lower signal on the instrument than other analytes. All matrix effect values 
calculated for extraction with MeOH:ACN were above the 25% threshold for ion 
enhancement at all concentrations, and therefore this combination was no longer considered. 
Figure 3.7 shows these trends at 15 ng/mL. This left extraction in 1:1 MeOH:ACN with 
addition of 1 mL of ACN or addition of 1 mL of ACN with 1% formic acid to the extraction 
solvent before filtration.  
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To further compare these two systems, the recovery of the two systems were 
considered. Between the recovery at 15 ng/mL and 150 ng/mL no significant difference was 
observed as the standard deviations overlapped between the two suggesting an overlap in the 
individual measurements of the replicates. However the average recovery tended to be higher 
for MeOH:ACN with 1 mL ACN. This same trend is seen at 450 ng/mL, where less overlap 
of the standard deviations for a number of drugs was observed showing a clear difference 
between the recoveries of the two systems. The higher average recovery and incidence of 
more ion enhancement than ion suppression across analytes and concentrations compared to 
extraction with 1:1 (v/v) MeOH:ACN with the addition of 1 mL of ACN with 1% formic acid 
lead to including a protein filtration step where extraction is completed using 1:1 (v/v) 
MeOH:ACN with the addition of 1 mL of ACN to the extraction solvent before filtration. 
The precision was acceptable for all analytes under all concentrations except TMZ with a 
CV% of 22.0 % from a 15 ng/mL DBS. As the precision over all other values was within < 
20%, this was not a significant parameter to consider when choosing the system.  
 
4.5 Reconstitution Solvent 
Benzodiazepines show a high binding affinity to plasma proteins suggesting they are 
more soluble in organic solvent than in an aqueous solvent [23]. In order to increase the 
recovery of analyte extracted from each spot after evaporation to dryness, a reconstitution 
solvent of 1:1 (v/v) ACN:H2O was compared to reconstitution in mobile phase A which was 
5mM ammonium formate in water with 1% formic acid. The aim was to include an organic 
solvent to restore more analyte into solution. The retention time resulting from the use of 
either reconstitution solvents was compared and no significant change in the value was 
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determined, allowing the continued identification of each analyte by that parameter. For all 
analytes and at all concentrations there was an increase in the recovery with the use of 1:1 
(v/v) ACN:H2O with the exception of 7CLZ that showed a decrease in recovery, as seen in 
Figure 3.9. This could be the result of the chemical properties of the compound, as it is a 
metabolite of CLZ, a product of the body metabolizing the drug by producing a more polar 
molecule more soluble in aqueous media such as urine for ease of elimination. This could 
explain a higher solubility of 7CLZ in mobile phase A compared to ACN:H2O. The observed 
increase in recovery for all drugs, especially those that already had a small observed signal 
such as LRZ and aHAM, resulted in the choice of ACN:H2O as the reconstitution solvent. 
 
4.6 Analyte Stability in DBS 
Stability of each benzodiazepine within the matrix of the Whatman 903 Protein Saver 
Cards was important to assess the time each card can be stored before interpretation of the 
concentration is complicated by change in the amount of analyte. Potential variations 
between storage conditions are also important to measure. The change expected to occur over 
time was degradation of the compound into the known metabolites included in this study or 
others not included in this study. Therefore a reduction in the measured response over time 
that deviated from the initial response measured on day 1 by 20% was considered a 
significant change in response.  Storage at ambient temperature and under refrigeration (4 °C) 
was compared at three levels (15, 150 and 450 ng/mL) in triplicate to see if there was a 
difference between the two storage conditions. It was expected that there would be less 
degradation observed under refrigeration as there would be less kinetic energy available in 
the system, slowing the spontaneous degradation of each analyte as well as lowering or 
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inhibiting enzyme activity within the blood. Figures 3.10 and 3.11 show the relative response 
change over time of temazepam compared to the initial measurement on day 1 at ambient 
temperature and under refrigeration respectively. The response fell below the 80% line at 28 
days under both conditions indicating a significant reduction of over 20% in signal from 
temazepam. This result indicated interpretation of concentration of temazepam is not reliable 
after 28 days, and can only be reliably interpreted within 14 days of storage. The exact point 
between 14 days and 28 days where relative response falls below that of 14 days is unknown, 
therefore the last day of measurement is the last day it can be said with certainty that the 
results do not show significant degradation.  
Temazepam is the only drug in the mix that demonstrated the expected degradation. 
The rest of the drugs exceeded a 20% change in the relative response demonstrated increases 
in signal. Demonstrated in Figure 3.12 and 3.13 showing the relative response change of 
alprazolam, at ambient temperature and refrigeration respectively. Over time the relative 
response change increases, until on day 28 the change in response exceeds 20%. This is 
observed at ambient temperature and refrigeration. Table 3.3 and Table 3.4 show the relative 
response change in percent for each analyte on day 14 and day 28 of storage respectively. Of 
the drugs that showed an increase in response, two , LRZ and 7CLZ, only changed at ambient 
temperature and with no significant change under refrigeration. This suggests that the analyte 
is stable for 28 days at 4°C so interpretation will not be affected up to 28 days, however, if 
left at ambient temperature, interpretation will only be reliable to 14 days. The other analytes 
showed an increase in response over time under both conditions after 28 days. Therefore 
interpretation of concentration would only remain unaffected up to 14 days for these 
compounds. All compounds that did not exhibit a change could be interpreted the same over 
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28 days if stored under both conditions. The increase of relative response over time to change 
beyond an additional 20% of the value on day 1 was an unexpected result that requires further 
testing to examine possible sources of the increase. An increase in signal would suggest an 
increase in the amount of analyte or increased recovery, however all spots of each 
concentration were made from the same aliquot of spiked blood, just stored within the cards 
over different time periods and extracted using the same method. There is the possibly that it 
is the result of a change in matrix effects, with compounds not measured in the blood 
degrading to new compounds that have a different effect on the analytes of interest. It could 
be certain compounds stabilizing in the card matrix and remaining held there rather than 
being removed with the extraction solvent, reducing background and therefore increasing the 
signal. Further experimentation is required. Most of the relative response changes observed 
were only observed at the low concentration, as the amount of sample spotted on the card is 
so small, and as an extension of that, the amount of analyte is limited. Modifications within 
the matrix may have significant effects whereas in larger quantities that effect is negligible.  
All compounds are stable up to 14 days under refrigeration. Refrigeration appears to stabilize 
more benzodiazepines included in this study than room temperature, and reliable 
interpretation is possible up to 14 days before compounds begin to show significant changes 
in relative response. 
 
4.7 Autosampler Stability 
The stability of each analyte must also be determined within the autosampler. This is 
assessing the stability of the analyte within the reconstitution solvent in the autosampler of 
the instrument while it waits to be sampled. It is the amount of time an analyte can remain 
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under those conditions before interpretation of the concentration is affected. The change 
expected, like with card stability, was degradation. A significant change was once again 
interpreted as a change in the relative response that is ±20% from the initial response 
measured at time zero. The relative change was measured at three concentrations (15.6, 125, 
and 500 ng/mL) in triplicate. Significant increases are indicated in the Table 3.6. The 
metabolite 7CLZ and LRZ showed a decrease in relative response at 15 ng/mL, standard 
deviation extended the variation beyond a 20% decrease in relative response, therefore 
interpretation of the concentration of these compounds can only reliably be made up to 24 
hours in the autosampler. All other values once again show a relative response increase 
beyond a 20% increase of the original value; a repeat of this experiment as well as 
investigation of matrix effects are required to assess this observed increase in OXZ, CLZ, and 
TMZ. Until this can be investigated and adjustments can be made if necessary to mediate this 
change, measurement is reliable up to 12 hours for all compounds. Further testing is required 
for CLZ, as the response increases beyond 20% at the 12 hours mark and no measurements 
were made at time points before that to see where the stability waivers. Instability is once 
again seen primarily in the low concentration samples.  
 
4.8 Hematocrit Effect 
The effect of hematocrit is an important consideration when it comes to dried blood 
spots (DBS). The volume fraction of blood occupied by red blood cells can affect the 
distribution of the blood components and analyte throughout the spot. Benzodiazepines are 
also a drug class demonstrating high binding affinity for plasma proteins, therefore the 
distribution of these components throughout the matrix and the quantity that are within a 
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DBS may have an effect on the measured response [23]. Within humans the normal range for 
hematocrit is 37-51% for adults but can reach between 20% and 80% of the total blood 
volume and above in cases of disease [46]. Therefore to cover the overall range of the human 
population response ratios at five different hematocrits were measured and compared: 20, 35, 
45, 55, and 70%. Another factor compared within the hematocrit levels was different drug 
concentrations: 15, 150, and 450 ng/mL. A Kruskal-Wallis non-parametric test was 
performed to measure if there were significant differences between the hematocrit values at 
each concentration. Figure 3.14 shows response across hematocrit levels for each drug at 15 
ng/mL. If a significant difference was calculated then a post-hoc Nemenyi style test was used 
to determine between which individual hematocrit values the significant differences were 
found. The Kruskal-Wallis non-parametric analysis found no significant differences for all 
drugs except LRZ and NDZ. LRZ had a statistically significant difference at 15 ng/mL 
between the two extremes of 20% and 70% and the rest of the hematocrits tested. NDZ had a 
calculated statistically significant difference that was determined at 150 ng/mL between 20% 
and 55% and all other hematocrit values. The values of all the differences calculated are 
found in Table 3.6. A p-value that was < 0.05 was considered to be significant; the calculated 
values were 0.045 and 0.048 respectively. The significant difference finding for NDZ at 150 
ng/mL was not expected, and the lack of difference observed at the lower concentration and 
the higher concentration was not easily interpreted. Also the significant difference between 
55% and all other hematocrit values occurring in the middle of the hematocrit range was 
difficult to rationalize. The mean values of the response ratios of both drugs that had a 
statistically significant value were compared. The mean response ratios upon comparison 
were not found to have although statistically significant were not significant differences. P-
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values calculated were very close to the 0.05 value that determines significance. A 
nonparametric test was performed because of the small number of repetitions (n=3) collected 
for each drug and hematocrit level, and a normality test may not have properly represented 
the data. However had the data actually demonstrated normality upon larger sampling, this 
may have caused differences in response but not significantly difference values. There is also 
the possibility that the variability in precision on this particular day of sampling was low and 
all data points were clustered closely around the same response ratio for each hematocrit. 
Repeating the experiment on multiple days in order to better determine the inter-day 
precision, and better establish the variability in the measured values would likely support the 
conclusion that there is no significant difference across the measured response ratio for the 
entire hematocrit range. There is also an increased probability of calculating a statistically 
significant difference the more comparisons completed, therefore a correction factor to 
account for this increased probability may be more representative of the true variation in the 
data. The final conclusion of this experiment was that there was no significant difference 
across the whole range of hematocrit found in the human population, and therefore there is no 
effect of hematocrit on the interpretation of response. However further testing repeating this 
experiment is required to establish inter-day variability in measurement. 
 
4.9 Method Validation: Calibration Curves and Accuracy 
The final step after development of the method and the determination of the effect of 
stability and hematocrit on interpretation was method validation. This was achieved by 
producing calibration curves for each analyte on five separate days and running two blind 
accuracy samples with each curve, one high and one low unknown concentration. Curves 
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were produced with data points of 7.8, 15.6, 31.25, 62.5, 125, 250, and 500 ng/mL. The limit 
of quantitation (LOQ) was determined to be the lowest point on the curve that demonstrated a 
precision of 20% and has a signal to noise ratio ≥10.  The limit of detection (LOD) was 
determined in this study to be equal to the LOQ as the lowest concentration that was 
measured on the curve. The R2 values that were produced for each curve showed a good fit 
with most having an R2 of 1.00. Only three of forty-five curves deviated from an R2 of 1.00 
and they were 0.998, 0.999, and 0.999 respectively. Each curve was fit with a quadratic 
regression line. Bias was calculated using the equation of the line of best fit to determine 
calculated concentration of each unknown blind sample, and then comparing the calculated 
value to the theoretical value. SWGTOX allows up to 20% deviation of the calculated 
concentration from the theoretical value (i.e. bias) to meet the guidelines for a quantitative 
method. All calculated bias values for all benzodiazepines met this criterion for the unknown 
high concentration, indicating a reliable quantitative method at the high end of the curve. 
However, most drugs demonstrated at least one bias value that exceeded this threshold over 
four curves at the unknown low concentration. Bias values never exceeded 25.6 % for the 
low concentrations and although this exceeded the threshold indicated by SWGTOX 
guidelines, this still indicated a close estimate of concentration. These guidelines tend to refer 
to extraction from ante-mortem samples rather than other mediums of collection, especially 
since DBS as a collection medium is just recently experiencing an increase in interest and 
research in forensic toxicology this threshold may be too conservative. Variability and 
reliability of quantitation from a curve extracted from DBS has not yet been established. 
Considering the difference in value that is obtained by a 25% deviation from the actual value, 
the interpretation of impairment will remain unchanged. Therefore the method, though not 
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validated to SWGTOX standards, does present a method that can be used to reliably estimate 
concentration values from DBS from a standard curve. However if through further testing it 
is found that a 20% change is reliable for DBS methods and bias extends beyond that 20% 
change, this method can still be used as a semi-quantitative method, used to determine if an 
individual was within an impairing range or not. It is also important to note that the standard 
curves were produced using Microsoft Excel where weighting of the regression line is not 
possible, therefore if using a software where weighting (1/X) was possible this may improve 
the calculated concentrations of the samples of unknown concentration. It is also important to 
note the lack of legal limits established for benzodiazepines in Canada mean that any 
identification of a benzodiazepine in a sample taken from a suspected drug impaired driver 
that corroborate the observations of the officer of impairment could result in conviction. 
 
4.10 Future Research 
The method that was developed and validated for this project is a good starting point 
for analysis of dried blood spots (DBS) when benzodiazepines are the analyte of interest. 
Further experiments are needed to assess the bias of blind accuracy samples using a weighted 
(1/X) quadratic regression line to better assess the performance of the method as a 
quantitative method. This method was developed and validated using sheep blood that had 
been spiked with a drug mix to produce each concentration evaluated. Subsequent sets of 
experiments should assess the matrix effects, recovery and precision of the method when 
taken from human blood, which would have differing components within the matrix that 
could change the results observed. Also the sheep blood that was used for the majority of the 
experiments was closer in properties to post-mortem blood rather than the ante-mortem blood 
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that would be expected in drug impaired driving cases. The red blood cells appeared to have 
begun to undergo hemolysis, and degradation products may have been present that would not 
be seen in ante-mortem blood. Applying the method to real samples, collected from 
individuals that have ingested a therapeutic or impairing quantity of one of the 
benzodiazepines of interest is the next step. Ideally this would also include a venous sample 
taken at the same time as the DBS in order to look at the correlation of venous concentration 
and capillary concentration. A difference has been observed between the two sources, as well 
as possibility of the inclusion of interstitial fluid from the puncture for DBS collection. 
Experiments to establish if a consistent correction factor can be established would be 
important for interpretation of concentrations determined from DBS. Further experiments 
measuring the effect of other storage conditions, such as freezing and the effect of humidity 
should also be performed along with matrix effect experiments to explore the observation of 
increased response of the analyte over time. As the goal was a screening method that could 
also be used to quantify the concentration of drug in the DBS and by extension at the time of 
detention, increasing the number of benzodiazepines as well as other prescription drugs and 
drugs of abuse that can successfully be extracted and analyzed using this method would be a 
good extension of this method. 
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CHAPTER 5: CONCLUSION 
Benzodiazepines are a class of drug that is commonly implicated in impaired driving 
cases. Blood is the preferred biological sample to be collected in order to establish blood 
concentration of the drug to support the finding of impairment by an officer. This study 
showed that nine benzodiazepine and benzodiazepine metabolites could be identified after 
extraction from DBS produced from only 20 µL of blood using a UPLC-QTOF-MS. The 
method functions as a screen for benzodiazepines, and also showed that it could be applied to 
quantification of concentration of a particular analyte.  
The development of this method showed optimization of each extraction and sample 
preparation step to minimize time and steps required. Validation showed potential for the use 
of the method to both identify and quantify each drug to reliably say if the concentration is 
consistent with impairment ranges known for each drug. Stability of each drug of interest was 
determined under two storage conditions within the matrix of the cards, establishing over 
what time period and under what storage a response can be considered consistent with the 
concentration at the initial time of collection as well as the stability of the extracts within the 
autosampler of the instrument waiting for analysis. 
A method with the potential for the simultaneous identification screen and 
quantification of identified analyte was developed, and with further research into important 
areas such as the method’s efficacy applied to ante-mortem human blood and the correlation 
between capillary and venous blood, the method could transition to use of real samples 
collected in incidences of drug impaired driving. This research could be expanded to include 
other drugs of interest for impaired driving. This is provided that legislation is changed for 
the collection of biological tests at the roadside. 
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APPENDIX: ADDITIONAL DATA FROM DBS ANALYSIS 
Table I: Average peak area measured at each time point during extraction by rapid agitation 
by the Tissuelyzer® of the time point comparison study at all 3 concentrations analyzed: 15, 
150 and 450 ng/mL. 
Conc  5min 10min 15min 30min 45min 60min  
15 ng/mL DZP 1177.70 148.02 19.26 0.00 0.00 0.00 
7-CLZ 373.08 69.28 0.00 0.00 0.00 0.00 
LRZ 49.047 8.41 0.00 0.00 0.00 0.00 
OXZ 74.14 9.68 0.00 0.00 0.00 0.00 
APZ 428.97 65.31 0.00 0.00 0.00 0.00 
CLZ 120.78 18.71 0.00 0.00 0.00 0.00 
NDZ 224.89 26.59 0.00 0.00 0.00 0.00 
aHAM 59.75 13.92 0.00 0.00 0.00 0.00 
TMZ 277.90 0.00 0.00 0.00 0.00 0.00 
OXZ- D5 1697.51 187.26 23.14 0.00 0.00 0.00 
7CLZ- D4 8693.51 1445.74 146.61 0.00 0.00 0.00 
NDZ-D5 4955.17 599.83 66.25 0.00 0.00 0.00 
APZ-D5 10097.15 932.93 90.45 12.66 0.00 0.00 
aHAM- D5 1174.18 137.94 8.66 0.00 0.00 0.00 
DZP-D5 29482.37 3139.38 360.40 38.01 57.17 17.05 
150 ng/mL DZP 21440.79 2956.61 380.34 89.72 91.46 47.18 
7-CLZ 4413.81 710.16 90.96 0.00 0.00 0.00 
LRZ 551.54 65.42 0.00 0.00 0.00 0.00 
OXZ 25945.59 2075.24 173.85 0.00 20.76 14.64 
APZ 838.25 116.64 11.01 0.00 0.00 0.00 
CLZ 8504.39 986.34 77.62 6.21 16.05 0.00 
NDZ 964.85 134.82 6.80 0.00 0.00 0.00 
aHAM 5531.66 672.21 57.28 0.00 8.87 1.04 
TMZ 2420.48 308.20 0.00 0.00 0.00 0.00 
OXZ- D5 1710.54 202.98 0.00 0.00 0.00 0.00 
7CLZ- D4 10221.62 1414.24 110.96 0.00 0.00 0.00 
NDZ-D5 43960.15 5089.86 469.27 89.71 136.08 86.5 
APZ-D5 4766.03 580.37 35.89 0.00 3.84 0.00 
aHAM- D5 10243.70 899.92 88.65 9.40 0.00 0.00 
DZP-D5 963.44 125.03 0.00 0.00 0.00 0.00 
450 ng/mL DZP 41757.44 4141.03 438.84 66.58 45.54 30.22 
7-CLZ 51966.47 8227.72 930.05 208.05 169.58 187.28 
LRZ 13873.51 1798.56 187.41 0.00 0.00 0.00 
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OXZ 1657.53 145.91 8.75 0.00 0.00 0.00 
APZ 57420.63 6884.14 318.55 29.65 46.95 36.11 
CLZ 1833.78 296.58 21.20 0.00 0.00 0.00 
NDZ 21455.51 2467.84 162.15 17.12 27.53 21.49 
aHAM 3135.95 291.91 11.31 0.00 0.00 0.00 
TMZ 8513.15 791.61 0.00 0.00 0.00 0.00 
OXZ- D5 1827.75 138.26 0.00 0.00 0.00 0.00 
7CLZ- D4 9835.40 1176.22 79.07 0.00 0.00 0.00 
NDZ-D5 44478.26 5155.91 365.93 82.64 155.68 97.98 
APZ-D5 4819.00 627.18 39.00 0.00 0.00 0.00 
aHAM- D5 9794.52 846.05 65.48 0.00 0.00 0.00 
DZP-D5 1001.63 106.42 0.00 0.00 0.00 0.00 
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Table II: Average peak area measured at each time point during extraction by sonication of 
the time point comparison study at all 3 concentrations analyzed: 15, 150 and 450 ng/mL. 
Conc  5min 10min 15min 30min 45min 60min  
15 ng/mL DZP 971.79 81.78 0.00 0.00 0.00 0.00 
7-CLZ 1211.26 150.27 0.00 0.00 0.00 0.00 
LRZ 279.41 38.03 0.00 0.00 0.00 0.00 
OXZ 42.26 8.59 0.00 0.00 0.00 0.00 
APZ 1898.82 175.19 12.71 0.00 0.00 0.00 
CLZ 78.47 0.00 0.00 0.00 0.00 0.00 
NDZ 659.80 57.79 0.00 0.00 0.00 0.00 
aHAM 92.59 7.26 0.00 0.00 0.00 0.00 
TMZ 432.74 40.14 0.00 0.00 0.00 0.00 
OXZ- D5 1218.88 138.13 0.00 0.00 0.00 0.00 
7CLZ- D4 7859.39 995.02 58.08 0.00 0.00 0.00 
NDZ-D5 39172.40 3933.29 335.30 95.07 61.47 58.95 
APZ-D5 4162.53 344.62 14.43 0.00 0.00 0.00 
aHAM- D5 6054.64 496.68 34.75 0.00 0.00 0.00 
DZP-D5 13.01 0.00 0.00 0.00 0.00 0.00 
150 ng/mL DZP 11809.05 933.11 69.82 0.00 0.00 0.00 
7-CLZ 17578.20 1586.75 154.30 61.76 49.53 46.90 
LRZ 3899.08 496.62 61.40 19.66 14.30 12.03 
OXZ 493.93 67.18 4.70 0.00 0.00 0.00 
APZ 26218.56 2148.34 103.85 13.67 0.00 0.00 
CLZ 831.85 101.57 9.74 0.00 0.00 0.00 
NDZ 8432.84 547.26 21.66 0.00 0.00 0.00 
aHAM 1051.76 84.50 7.78 0.00 0.00 0.00 
TMZ 5243.96 431.28 31.80 0.00 0.00 0.00 
OXZ- D5 1176.70 133.10 0.00 0.00 0.00 0.00 
7CLZ- D4 9295.53 939.43 91.56 #DIV/0! 0.00 0.00 
NDZ-D5 42492.98 3737.39 331.51 99.78 67.94 67.32 
APZ-D5 4114.29 325.53 24.15 0.00 0.00 0.00 
aHAM- D5 5712.51 467.64 36.54 0.00 0.00 0.00 
DZP-D5 28.03 0.00 0.00 0.00 0.00 0.00 
450 ng/mL DZP 35778.20 2875.07 189.44 21.36 0.00 0.00 
7-CLZ 49556.10 5056.56 437.61 170.33 154.60 120.76 
LRZ 11799.70 1556.07 155.86 59.18 45.76 43.74 
OXZ 1443.84 185.57 20.13 0.00 0.00 0.00 
APZ 65787.40 6811.62 337.38 37.14 19.47 13.90 
CLZ 2499.69 270.80 13.10 0.00 0.00 0.00 
NDZ 26575.46 1668.23 73.85 7.35 0.00 0.00 
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aHAM 3202.29 317.25 18.50 0.00 0.00 0.00 
TMZ 15954.87 1312.55 78.22 0.00 0.00 0.00 
OXZ- D5 1098.50 118.17 0.00 0.00 0.00 0.00 
7CLZ- D4 8457.44 926.78 72.66 0.00 0.00 0.00 
NDZ-D5 39238.90 3646.11 273.47 81.56 61.95 56.89 
APZ-D5 3810.11 311.01 18.64 0.00 0.00 0.00 
aHAM- D5 5462.45 438.98 30.59 0.00 0.00 0.00 
DZP-D5 6.26 0.00 0.00 0.00 0.00 0.00 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   V	  
Table III: Average peak area measured at each time point during extraction by vortexing of 
the time point comparison study at all 3 concentrations analyzed: 15, 150 and 450 ng/mL. 
Conc  5min 10min 15min 30min 45min 60min  
15 ng/mL DZP 1013.53 52.83 0.00 0.00 0.00 0.00 
7-CLZ 1617.82 145.15 0.00 0.00 0.00 0.00 
LRZ 328.05 23.36 0.00 0.00 0.00 0.00 
OXZ 51.00 12.07 0.00 0.00 0.00 0.00 
APZ 2324.80 159.05 18.58 0.00 0.00 0.00 
CLZ 71.70 0.00 0.00 0.00 0.00 0.00 
NDZ 602.83 7.16 0.00 0.00 0.00 0.00 
aHAM 99.42 12.54 0.00 0.00 0.00 0.00 
TMZ 422.98 33.83 0.00 0.00 0.00 0.00 
OXZ- D5 1072.50 98.18 0.00 0.00 0.00 0.00 
7CLZ- D4 5654.71 505.04 46.99 0.00 0.00 0.00 
NDZ-D5 30673.30 2316.16 177.21 57.15 30.69 20.89 
APZ-D5 3254.32 166.62 20.11 0.00 0.00 0.00 
aHAM- D5 6936.49 445.21 39.86 3.31 0.00 0.00 
DZP-D5 850.32 63.44 0.00 0.00 0.00 0.00 
150 ng/mL DZP 9363.93 628.15 54.94 0.00 0.00 0.00 
7-CLZ 15517.19 1391.94 117.29 40.33 19.71 17.25 
LRZ 2824.94 311.37 31.73 9.97 0.00 0.00 
OXZ 426.55 47.36 #DIV/0! 0.00 0.00 0.00 
APZ 25380.78 1589.37 140.80 23.88 0.00 0.00 
CLZ 651.91 61.27 0.00 0.00 0.00 0.00 
NDZ 5500.00 99.93 9.55 0.00 0.00 0.00 
aHAM 950.52 90.43 8.28 0.00 0.00 0.00 
TMZ 3996.44 309.13 25.29 0.00 0.00 0.00 
OXZ- D5 1097.77 98.86 14.17 0.00 0.00 0.00 
7CLZ- D4 5594.25 551.96 42.64 0.00 0.00 0.00 
NDZ-D5 30544.76 2622.49 215.84 69.23 35.89 22.90 
APZ-D5 3303.43 237.44 23.70 0.00 0.00 0.00 
aHAM- D5 7341.45 507.76 44.11 0.00 0.00 0.00 
DZP-D5 881.88 65.97 10.94 0.00 0.00 0.00 
450 ng/mL DZP 27262.07 1624.33 119.68 18.19 18.19 0.00 
7-CLZ 45197.52 3618.56 266.15 109.81 59.38 37.05 
LRZ 8409.53 803.81 64.37 34.00 13.74 0.00 
OXZ 1186.64 118.03 10.99 0.00 0.00 0.00 
APZ 66400.31 4405.21 310.29 50.99 12.54 0.00 
CLZ 1797.06 165.17 0.00 0.00 0.00 0.00 
NDZ 16102.01 400.23 23.24 13.15 0.00 0.00 
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aHAM 2784.99 220.96 17.52 0.00 0.00 0.00 
TMZ 11096.24 772.68 52.52 8.09 0.00 0.00 
OXZ- D5 1044.23 91.74 0.00 0.00 0.00 0.00 
7CLZ- D4 5593.47 498.35 43.80 0.00 0.00 0.00 
NDZ-D5 29776.07 2276.56 171.37 52.57 30.46 27.77 
APZ-D5 3171.61 213.03 18.38 0.00 0.00 0.00 
aHAM- D5 6945.40 425.42 34.29 0.00 0.00 0.00 
DZP-D5 864.53 59.60 0.00 0.00 0.00 0.00 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   VII	  
 
Table IV: Relative recovery of each analyte at each time point sampled at each 
concentration after extraction by rapid agitation by Tissuelyzer®. 
 
Conc.  Relative Recovery (%) 
5 min 10 min 15 min 30 min 45 min 60 min 
15 ng/mL DZP 88.60 138.75 10.28 15.16 1.12 0 
NDZ 91.05 21.76 8.95 0.00 0.00 0.00 
TMZ 100 0.00 0.00 0.00 0.00 0.00 
OXZ 89.62 8.80 10.38 0.00 0.00 0.00 
LRZ 82.96 9.82 17.04 0.00 0.00 0.00 
APZ 88.72 54.92 11.28 0.00 0.00 0.00 
aHAM 82.55 14.93 17.45 0.00 0.00 0.00 
CLZ 86.17 19.23 13.83 0.00 0.00 0.00 
7CLZ 85.40 67.61 14.60 0.00 0.00 0.00 
150 
ng/mL 
DZP 86.55 156.30 11.66 24.06 1.79 0.00 
NDZ 87.96 30.23 12.04 0.00 0.00 0.00 
TMZ 88.71 11.29 0.00 0.00 0.00 0.00 
OXZ 86.50 10.82 13.50 0.00 0.00  
LRZ 85.53 7.88 14.47 0.00 0.00 0.00 
APZ 84.57 75.20 15.43 0.00 0.00 0.00 
aHAM 84.29 10.51 15.71 0.00 0.00 0.00 
CLZ 87.80 17.20 12.20 0.00 0.00 0.00 
7CLZ 85.54 55.95 14.46 0.00 0.00 0.00 
450 
ng/mL 
DZP 87.54 149.01 11.08 18.57 1.38 0.00 
NDZ 89.31 27.79 10.69 0.00 0.00 0.00 
TMZ 91.49 8.51 0.00 0.00 0.00 0.00 
OXZ 89.12 9.42 10.88 0.00 0.00 0.00 
LRZ 87.50 7.54 12.50 0.00 0.00 0.00 
APZ 87.06 65.80 12.94 0.00 0.00 0.00 
aHAM 76.18 16.33 23.82 0.00 0.00 0.00 
CLZ 85.78 19.70 14.22 0.00 0.00 0.00 
7CLZ 82.33 84.29 17.67 0.00 0.00 0.00 
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Table V: Relative recovery of each analyte at each time point sampled at each 
concentration after extraction by vortexing. 
 
Conc.  Relative Recovery (%) 
5 min 10 min 15 min 30 min 45 min 60 min 
15 ng/mL DZP 95.05 4.95 0.00 0.00 0.00 0.00 
NDZ 91.55 8.45 0.00 0.00 0.00 0.00 
TMZ 92.59 7.41 0.00 0.00 0.00 0.00 
OXZ 100.00 0.00 0.00 0.00 0.00 0.00 
LRZ 80.86 19.14 0.00 0.00 0.00 0.00 
APZ 92.59 7.41 0.00 0.00 0.00 0.00 
aHAM 100.00 0.00 0.00 0.00 0.00 0.00 
CLZ 90.51 9.49 0.00 0.00 0.00 0.00 
7CLZ 93.35 6.65 0.00 0.00 0.00 0.00 
150 
ng/mL 
DZP 93.20 6.25 0.55 0.00 0.00 0.00 
NDZ 91.61 7.83 0.56 0.00 0.00 0.00 
TMZ 92.28 7.14 0.58 0.00 0.00 0.00 
OXZ 91.41 8.59 0.00 0.00 0.00 0.00 
LRZ 90.01 9.99 0.00 0.00 0.00 0.00 
APZ 92.28 7.14 0.58 0.00 0.00 0.00 
aHAM 90.20 9.80 0.00 0.00 0.00 0.00 
CLZ 90.37 8.63 1.00 0.00 0.00 0.00 
7CLZ 88.89 9.80 1.00 0.31 0.00 0.00 
450 
ng/mL 
DZP 93.87 5.59 0.41 0.06 0.06 0.00 
NDZ 92.53 6.92 0.55 0.00 0.00 0.00 
TMZ 93.01 6.48 0.44 0.07 0.00 0.00 
OXZ 91.58 8.42 0.00 0.00 0.00 0.00 
LRZ 90.19 8.97 0.84 0.00 0.00 0.00 
APZ 93.01 6.48 0.44 0.07 0.00 0.00 
aHAM 91.57 8.43 0.00 0.00 0.00 0.00 
CLZ 91.70 7.69 0.61 0.00 0.00 0.00 
7CLZ 90.18 8.62 0.69 0.36 0.15 0.00 
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Table VI: Relative recovery of each analyte at each time point sampled at each 
concentration after extraction by vortexing. 
 
Conc.  Relative Recovery (%) 
5 min 10 min 15 min 30 min 45 min 60 min 
15 ng/mL DZP 92.24 7.76 0.00 0.00 0.00 0.00 
NDZ 93.83 6.17 0.00 0.00 0.00 0.00 
TMZ 91.51 8.49 0.00 0.00 0.00 0.00 
OXZ 100.00 0.00 0.00 0.00 0.00 0.00 
LRZ 83.11 16.89 0.00 0.00 0.00 0.00 
APZ 91.51 8.49 0.00 0.00 0.00 0.00 
aHAM 100.00 0.00 0.00 0.00 0.00 0.00 
CLZ 94.57 5.43 0.00 0.00 0.00 0.00 
7CLZ 88.02 11.98 0.00 0.00 0.00 0.00 
150 
ng/mL 
DZP 92.17 7.28 0.54 0.00 0.00 0.00 
NDZ 91.18 8.33 0.49 0.00 0.00 0.00 
TMZ 91.89 7.56 0.56 0.00 0.00 0.00 
OXZ 88.20 10.77 1.03 0.00 0.00 0.00 
LRZ 87.30 11.87 0.83 0.00 0.00 0.00 
APZ 91.89 7.56 0.56 0.00 0.00 0.00 
aHAM 90.59 9.41 0.00 0.00 0.00 0.00 
CLZ 90.01 9.39 0.61 0.00 0.00 0.00 
7CLZ 86.59 11.03 1.36 0.44 0.32 0.27 
450 
ng/mL 
DZP 92.06 7.40 0.49 0.05 0.00 0.00 
NDZ 91.24 8.13 0.63 0.00 0.00 0.00 
TMZ 91.98 7.57 0.45 0.00 0.00 0.00 
OXZ 89.80 9.73 0.47 0.00 0.00 0.00 
LRZ 87.53 11.25 1.22 0.00 0.00 0.00 
APZ 91.98 7.57 0.45 0.00 0.00 0.00 
aHAM 90.32 9.56 0.12 0.00 0.00 0.00 
CLZ 92.48 6.83 0.69 0.00 0.00 0.00 
7CLZ 86.38 11.39 1.14 0.43 0.33 0.32 
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Figure I: Coefficient of variation in percent of each analyte (DZP, 7CLZ, LRZ, OXZ, APZ, 
CLZ, NDZ, aHAM, TMZ) measured from DBS at 150 ng/mL after 5 minutes of extraction 
comparing each of the 3 agitation methods (Tissuelyzer®, sonication, vortexing). Each value 
was made from measurements made in triplicate (n=3). 
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Figure II: Coefficient of variation in percent of each analyte (DZP, 7CLZ, LRZ, OXZ, 
APZ, CLZ, NDZ, aHAM, TMZ) measured from DBS at 450 ng/mL after 5 minutes of 
extraction comparing each of the 3 agitation methods (Tissuelyzer®, sonication, vortexing). 
Each value was made from measurements made in triplicate (n=3). 
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Table VII: Results of recovery for all analytes at all concentrations for all extraction 
solvents tested for optimization during method development. 
 
Extraction 
Solvent 
Analyte Recovery (%) 
15 ng/mL 150 ng/mL 450 ng/mL 
MeOH DZP 130.12 154.43 139.32 
7CLZ 63.76 79.08 74.14 
LRZ 61.73 75.26 64.80 
OXZ 121.44 149.42 137.99 
APZ 116.59 145.16 119.68 
CLZ 131.42 146.34 140.31 
NDZ 129.92 159.52 141.33 
aHAM 129.41 159.73 142.22 
TMZ 129.91 163.57 155.09 
MeOH with 1% 
FA 
DZP 181.6726797 155.2485994 182.8520653 
7CLZ 58.30743844 45.44657459 51.95697504 
LRZ 156.1293952 178.2396279 202.5519997 
OXZ 258.8449194 178.3271816 186.0537493 
APZ 177.0389713 148.1095431 173.4883736 
CLZ 221.8633634 203.1124231 225.1315936 
NDZ 210.7063427 175.4382271 202.7322019 
aHAM 141.306308 118.5313661 137.8555877 
TMZ 269.5012017 163.3414885 192.3839303 
MeOH:ACN DZP 168.0 152.5 157.5 
7CLZ 83.6 78.5 79.2 
LRZ 155.6 145.1 146.9 
OXZ 166.0 144.2 149.7 
APZ 161.3 152.2 154.3 
CLZ 152.2 147.1 148.2 
NDZ 173.8 152.7 160.5 
aHAM 169.6 154.2 153.9 
TMZ 163.3 146.1 153.8 
MeOH:ACN with 
1% FA 
DZP 183.89 164.69 188.15 
7CLZ 70.88 59.63 64.17 
LRZ 189.22 183.80 207.01 
OXZ 205.46 180.60 206.56 
APZ 230.23 200.41 253.56 
CLZ 237.88 220.17 268.59 
NDZ 222.14 190.91 226.04 
aHAM 151.38 149.75 169.20 
TMZ 248.84 188.11 218.48 
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Figure III: Calcualted matrix effects (±SD) of each benzodiazpine from each solvent 
system measured to optimize protein filtration with a Clean Screen® FASt plate: 1:1 (v/v) 
MeOH:ACN (methanol: acetonitrile); MeOH:ACN with 1% formic acid (FA); 1:1 (v/v) 
MeOH:ACN with 1 mL ACN added post-extraction before filtration; 1:1 (v/v) MeOH:ACN 
with 1 mL ACN with 1% FA added post-extraction before filtration. These data are 
calculated from 150 ng/mL DBS measured in triplicate(n=3). 
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Figure IV: Calcualted matrix effects (±SD) of each benzodiazpine from each solvent 
system measured to optimize protein filtration with a Clean Screen® FASt plate: 1:1 (v/v) 
MeOH:ACN (methanol: acetonitrile); MeOH:ACN with 1% formic acid (FA); 1:1 (v/v) 
MeOH:ACN with 1 mL ACN added post-extraction before filtration; 1:1 (v/v) MeOH:ACN 
with 1 mL ACN with 1% FA added post-extraction before filtration. These data are 
calculated from 450 ng/mL DBS measured in triplicate(n=3). 
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Figure V: Calculated recovery (±SD) of each benzodiazepine extracted with MeOH:ACN 
with the addition of 1 mL of ACN to the extraction solvent before filtration compared to 
extraction with MeOH:ACN with the addition of 1 mL of ACN with 1% of formic acid 
(FA) to optimize the solvent system. These data are calculated from DBS at 150 ng/mL 
collected in triplicate (n=3). 
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Figure VI: Calculated recovery (±SD) of each benzodiazepine extracted with MeOH:ACN 
with the addition of 1 mL of ACN to the extraction solvent before filtration compared to 
extraction with MeOH:ACN with the addition of 1 mL of ACN with 1% of formic acid 
(FA) to optimize the solvent system. These data are calculated from DBS at 450 ng/mL 
collected in triplicate (n=3). 
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Table VIII: Calculated bias for both the low and high blind accuracy samples determined 
from the equation of the line of best fit. 
Average Bias (%) 
Low Accuracy 
Sample 
Analyte Curve 2 Curve 3 Curve 4 Curve 5 
DZP 14.80 22.23 15.42 1.65 
7CLZ 16.58 11.02 25.43 11.29 
LRZ 12.27 10.01 10.39 12.20 
OXZ 16.91 21.80 13.61 9.35 
APZ 11.75 19.22 10.99 9.57 
CLZ 16.30 21.37 11.67 8.15 
NDZ 16.56 23.14 23.72 8.34 
aHAM 21.66 25.61 18.32 12.01 
TMZ 12.49 14.80 20.16 9.11 
High Accuracy 
Sample 
DZP 15.86 15.20 13.37 2.96 
7CLZ 16.21 15.76 16.25 4.16 
LRZ 16.20 16.32 3.30 4.30 
OXZ 12.76 13.38 10.09 3.09 
APZ 15.91 12.18 10.86 3.62 
CLZ 18.48 15.66 10.16 3.16 
NDZ 16.66 15.09 8.62 2.15 
aHAM 12.93 13.74 13.49 2.29 
TMZ 13.19 10.20 7.73 4.38 
 
